document incorporate reference part ii iii portion registrant annual report shareholder fiscal year annual report part iii portion registrant proxy statement annual meeting shareholder file day close registrant fiscal year proxy statementitem pag e business general segment business geographic area raw material patent trademark seasonality competition research development environment regulation available information risk factor b unresolved staff comment property legal proceeding submission matter vote security holder executive officer registrant ii market registrant common equity relate stockholder matter issuer purchase equity security select financial datum management discussion analysis financial condition result operation quantitative qualitative disclosure market risk financial statement supplementary data change disagreement accountant account financial disclosure control procedure b information iii director executive officer corporate governance executive compensation security ownership certain beneficial owner management relate stockholder matter certain relationship relate transaction director independence principal accountant fee service iv exhibit financial statement schedule schedule ii valuation qualifying account signature report independent register public accounting firm financial statement schedule exhibit index exj amendment certificate extra compensation plan exl amendment defer fee plan director exn amendments executive income deferral plan exp amendments johnson johnson excess saving plan exr amendment excess benefit plan exv summary compensation arrangement exw severance arrangement alex gorsky ex statement computation ratio earning fix charge ex page company annual report shareholder ex subsidiary ex consent independent register public accounting firm exa certification exb certification exa certification exb certification ex cautionary statementtable content item business general johnson johnson subsidiary approximately employee worldwide engage research development manufacture sale broad range product health care field johnson johnson hold company operate company conduct business virtually country world johnson johnsons primary focus product relate human health wellbee johnson johnson incorporate state new jersey companys structure base principle decentralize management executive committee johnson johnson principal management group responsible operation allocation resource company committee oversee coordinate activitie consumer pharmaceutical medical device diagnostic business segment subsidiary business segment exception manage citizen country locate segment business johnson johnsons operating company organize business segment consumer pharmaceutical medical device diagnostic additional information require item incorporate reference narrative tabular graphic description segment operate result caption management discussion analysis result operation financial condition page note segment business geographic area note consolidated financial statement annual report file exhibit report consumer consumer segment include broad range product baby care skin care oral care wound care womens health care field nutritional overthecounter pharmaceutical product baby care franchise include johnson baby line product major brand skin care franchise include aveeno clean clear johnson adult neutrogena roc lubriderm beijing dabao cosmetics co ltd vendme product line oral care franchise include listerine reach oral care line product major brand women health franchise carefree pantiliners stayfree sanitary protection product nutritional overthecounter line include splenda calorie sweetener broad family tylenol acetaminophen product sudafe cold flu allergy product zyrtec allergy product motrin ib ibuprofen product pepcid ac acid controller johnson johnson merck consumer pharmaceutical co product market principally general public sell wholesaler directly independent chain retail outlet world pharmaceutical pharmaceutical segment include product follow therapeutic area antiinfective antipsychotic cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management urology virology product distribute directly retailer wholesaler health care professional prescription use general public key product pharmaceutical segment include remicade infliximab biologic approve treatment crohns disease ankylose spondylitis psoriasis psoriatic arthritis ulcerative colitis use treatment rheumatoid arthritis topamax topiramate approve adjunctive monotherapy use epilepsy prophylactic treatment migraine procrit epoetin alfa sell outside eprex biotechnologyderive product stimulate red blood cell production risperdal oral risperidone medication treat symptom schizophrenia bipolar mania irritability associate autistic behavior indicate patient risperdal consta risperidone longacte injectable invegatm paliperdone extendedrelease tablet treatment schizophrenia levaquin levofloxacin floxin ofloxacin antiinfective field concerta methylphenidate hcl product treatment attention deficit hyperactivity disorder aciphexpariet proton pump inhibitor comarketed eisai inc duragesicfentanyl transdermal fentanyl transdermal system sell outside durogesic treatment chronic pain offer novel delivery systemtable content medical device diagnostic medical device diagnostic segment include broad range product distribute wholesaler hospital retailer principally professional field physician nurse therapist hospital diagnostic laboratory clinic product include cordis circulatory disease management product depuy orthopaedic joint reconstruction spinal care sport medicine product ethicon surgical care women health product ethicon endosurgerys minimally invasive surgical product lifescan blood glucose monitor insulin delivery product orthoclinical diagnostic professional diagnostic product vistakon disposable contact lense distribution health care professional market directly surgical supply dealer geographic area international business johnson johnson conduct subsidiary locate country outside united states sell product virtually country world product sell international business include describe segment business consumer pharmaceutical medical device diagnostic principal market product method distribution international business vary country culture product sell international business include develop united states develop subsidiary abroad investment activity country outside united states subject high risk comparable activity investment commercial climate influence restrictive economic policy political uncertainty raw material raw material essential johnson johnsons operate company business generally readily available multiple source patent trademark johnson johnson operating company practice obtain patent protection product process possible licensed number patent relate product manufacturing process aggregate believe material importance johnson johnson operation business sale company large product remicade infliximab topamax topiramate account approximately johnson johnsons total revenue respectively fiscal accordingly patent relate product believe material johnson johnson material patent expire related risperdal risperidone expire united states december topamax expire united states september company receive pediatric extension risperdal oral topamax fda grant market exclusivity united states june march respectively significant patent schedule expire december levaquin levofloxacin account company sale pediatric extension levaquin grant fda extend market exclusivity united states june johnson johnsons operating company practice sell product trademark obtain protection trademark available mean trademark protect registration united states country product market johnson johnson consider trademark aggregate material importance operation business table content seasonality worldwide sale reflect significant degree seasonality spend heavy fourth quarter year quarter reflect increase spending decision principally advertise research development activity competition product line johnson johnsons operating company compete company large small locate world competition strong product line regard number size compete company involve competition research involve development improvement new exist product process particularly significant development new improve product important johnson johnson success area business include protect company portfolio intellectual property competitive environment require substantial investment continue research multiple sale force addition development maintenance customer acceptance product johnson johnsons consumer business involve significant expenditure advertising promotion research development research activity represent significant johnson johnson subsidiary business major research facility locate united states belgium brazil canada china france germany india japan netherlands singapore united kingdom cost worldwide companysponsore research activity relate development new product improvement exist product technical support product compliance governmental regulation protection consumer patient exclude inprocess research development charge amount billion billion billion fiscal year respectively cost charge directly expense directly income year incur environment johnson johnsons operate company subject variety federal state local environmental protection measure johnson johnson believe operation comply material respect applicable environmental law regulation johnson johnson compliance requirement past year expect material effect capital expenditure cash flow earning competitive position regulation johnson johnson business subject vary degree governmental regulation country operation conduct general trend increasingly stringent regulation united states drug device diagnostic cosmetic industry long subject regulation federal state agency primarily product safety efficacy manufacturing advertising labeling safety report exercise broad regulatory power fda continue result increase amount test documentation require fda clearance new drug device correspond increase expense product introduction similar trend evident major market outside united states cost human health care continue subject study investigation regulation governmental agency legislative body world united states attention focus drug price profit program encourage doctor write prescription particular drug recommend use purchase particular medical device payer potent force market place increase attention pay drug medical device price appropriate drug medical device utilization quality cost health care united states implementation medicare prescription drug improvement modernization act deficit reduction act cause uncertainty reimbursement level certain product segment table content regulatory agency purview johnson johnsons operate company operate administrative power subject company action product withdrawal recall seizure product civil criminal sanction case johnson johnson operating company deem advisable initiate product recall addition business practice health care industry come increase scrutiny particularly united states government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty available information company main corporate web site address wwwjnjcom copy johnson johnsons quarterly report form q annual report current report form k file furnish securities exchange commission sec amendment foregoing provide charge shareholder submit write request secretary principal executive office company call company sec filing available company web site wwwinvestorjnjcomgovernancecfm soon reasonably practicable electronically file furnish sec sec filing available sec web site wwwsecgov addition write charter audit committee compensation benefit committee nominate corporate governance committee board director company principle corporate governance policy business conduct employee code business conduct ethic member board director executive officer available wwwinvestorjnjcomgovernancecfm web site address provide charge shareholder submit write request provide item risk factor applicable item b unresolved staff comment applicable item property johnson johnson subsidiary operate manufacturing facility occupy approximately million square foot floor space manufacturing facility industry segment johnson johnsons business approximately follow square foot segment thousand consumer pharmaceutical medical device diagnostic worldwide total united states facility consumer segment pharmaceutical segment medical device diagnostic segment johnson johnsons manufacturing operation outside united states conduct facility serve business segment table content location manufacture facility major geographic area world follow square foot number geographic area facility thousands united states europe western hemisphere exclude africa asia pacific worldwide total addition manufacture facility discuss johnson johnson subsidiary maintain numerous office warehouse facility world research facility discuss item business research development johnson johnson subsidiary generally seek manufacture facility principally location abroad lease office warehouse facility lease johnson johnson property maintain good operating condition repair utilize information lease obligation note rental expense lease commitment note consolidated financial statement annual report file exhibit report segment information addition property plant equipment contain note segment business geographic area note consolidated financial statement annual report file exhibit report item legal proceeding information set forth note legal proceeding note consolidated financial statement page annual report incorporate reference file exhibit report company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state law primary relief seek cost past future remediation feasible predict determine outcome proceeding opinion company proceeding material adverse effect result operation cash flow financial position company item submission matter vote security holder applicable executive officer registrant list executive officer johnson johnson february indicate employee company affiliate hold position indicate past year family relationship executive officer arrangement understand executive officer person pursuant executive officer select annual meeting board director executive officer elect board hold office year respective successor elect qualified early resignation removal table content information regard director company include follow executive officer director incorporate reference material caption election director proxy statement age position dominic j caruso member executive committee vice president finance chief financial officera donald casey jr member executive committee worldwide chairman comprehensive care groupb russell c deyo member executive committee vice president general counselc kaye fostercheek member executive committee vice president human resourcesd colleen goggin member executive committee worldwide chairman consumer groupe alex gorsky member executive committee worldwide chairman surgical care groupf sherilyn mccoy member executive committee worldwide chairman pharmaceuticals groupg christine poon vice chairman board directors member executive committeeh nicholas j valeriani member executive committee vice president office strategy growthi william c weldon chairman board directors chairman executive committee chief executive officer mr j caruso join company company acquire centocor inc time acquisition senior vice president finance centocor mr caruso name vice president finance orthomcneil pharmaceutical inc vice president group finance company medical device diagnostic group mr caruso name vice president company group finance organization mr caruso member executive committee vice president finance chief financial officer b mr casey jr join company hold position president johnson johnson merck consumer pharmaceutical co name president personal product company division johnson johnson consumer companies inc mr casey group president johnson johnson vision care inc name company group chairman vision care name company group chairman lifescan franchise member executive committee worldwide chairman comprehensive care group c mr r c deyo join company associate general counsel member executive committee vice president administration vice president general counsel ms k fostercheek join company vice president human resources johnson johnson consumer product company name vice president human resource consumer personal care group name member human resource leadership team consumer personal care group operating committee ms fostercheek member executive committee vice president human resource company prior join company ms fostercheek serve human resource management position pfizer inc year recently support pharmaceutical business japan asia africa middle east latin america e ms c goggins join company hold position president personal product company name president johnson johnson consumer companies inc company group chairman north america johnson johnson consumer product ms goggin member executive committee worldwide chairman consumer personal care group know consumer group table content f mr gorsky join company company group chairman worldwide franchise chairman ethicon inc previously head north american pharmaceuticals business novartis pharmaceutical corporation prior novartis mr gorsky serve management position johnson johnson include company group chairman company pharmaceutical business europe middle east africa president janssen pharmaceutica inc january member executive committee worldwide chairman surgical care group g ms mccoy join company associate scientist research development personal product company name vice president research development personal product worldwide division mcneilppc inc vice president marketing skin care franchise ms mccoy global president baby wound care franchise name company group chairman worldwide franchise chairman ethicon inc member executive committee worldwide chairman surgical care group january worldwide chairman pharmaceutical group h ms c poon join company company group chairman pharmaceutical group member executive committee worldwide chairman pharmaceutical group name worldwide chairman medicine nutritional appoint vice chairman company board director name worldwide chairman pharmaceutical group prior join company ms poon serve management position bristolmyer squibb company year recently president international medicine president medical devices ms poon plan retire company march mr n j valeriani join company hold position president ethicon endosurgery inc name company group chairman ethicon endo surgery additional responsibility johnson johnson medical product medical device diagnostic business canada worldwide franchise chairman depuy franchise mr valeriani member executive committee vice president human resource assume additional responsibility worldwide chairman diagnostic mr valeriani appoint worldwide chairman cardiovascular device diagnostic relinquish human resource responsibility worldwide chairman medical device diagnostic group mr valeriani vice president office strategy growth ii item market registrant common equity relate stockholder matter issuer purchase equity security february record holder common stock company additional information call item incorporate reference material caption management discussion analysis result operation financial condition liquidity capital resource share repurchase dividend information common stock market price note common stock stock option plan stock compensation agreement note consolidated financial statement page shareholder return performance graph annual report file exhibit report item security ownership certain beneficial owner management relate stockholder matter equity compensation plan information report issuer purchase equity securities july company announce board director approve stock repurchase program authorize company buy billion company common stock share repurchase place open market time time base market condition repurchase program time limit suspend period discontinue time share acquire available general corporate purpose company fund share repurchase program combination available cash debt company expect triplea credit rating affect share repurchase program table content addition common stock purchase open market systematic plan relate company compensation program follow table provide information respect common stock purchase company fiscal fourth quarter total number share remain purchase maximum number share total number avg price publicly announce purchase share pay plan plan period purchase share program programs september october october november november december total fiscal fourth quarter company repurchase aggregate share company common stock pursuant repurchase program publicly announce july aggregate share openmarket transaction outside program december base closing price company common stock new york stock exchange december share december aggregate share purchase total billion inception repurchase program announce july item select financial datum information call item incorporate reference material caption summary operation statistical datum annual report file exhibit report item management discussion analysis financial condition result operation information call item incorporate reference narrative tabular graphic material caption management discussion analysis result operation financial condition page annual report file exhibit report item quantitative qualitative disclosure market risk information call item incorporate reference material caption management discussion analysis result operation financial condition liquidity capital resource finance market risk note summary significant accounting policy financial instrument note consolidated financial statement page annual report file exhibit report item financial statement supplementary datum information call item incorporate reference audit consolidated financial statement note thereto material caption report independent register public accounting firm page annual report file exhibit report table content item change disagreement accountant account financial disclosure applicable item control procedure disclosure control procedure end period cover report company evaluate effectiveness design operation disclosure control procedure company disclosure control procedure design ensure information require disclose company report file submit exchange act record process summarize report time period specify sec rule form disclosure control procedure include limitation control procedure design ensure information require disclose company report file submit exchange act accumulate communicate company management include principal executive principal financial officer person perform similar function appropriate allow timely decision require disclosure william c weldon chairman chief executive officer dominic j caruso chief financial officer review participate evaluation base evaluation messr weldon caruso conclude end period cover report company disclosure control procedure effective management report internal control financial reporting section sarbanesoxley act management require assess effectiveness company internal control financial reporting end fiscal year report base assessment company internal control financial report effective management company responsible establish maintain adequate internal control financial reporting company internal control financial reporting design provide reasonable assurance reliability company financial reporting preparation external financial statement accordance generally accept accounting principle internal control financial reporting matter design inherent limitation internal control financial reporting determine effective provide reasonable assurance respect financial statement preparation prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate company management assess effectiveness company internal control financial reporting december make assessment company criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework criterion area control environment risk assessment control activity information communication monitoring company assessment include extensive documenting evaluating testing design operating effectiveness internal control financial reporting base company process assessment describe management conclude december company internal control financial report effective effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear report independent register public accounting firm annual report incorporate reference file exhibit report change internal control financial reporting fiscal quarter end december change companys internal control financial reporting identify connection evaluation refer item materially affect reasonably likely materially affect company internal control financial reporting item b information applicable table content iii item director executive officer corporate governance information call item incorporate reference material caption election director stock ownership section compliance section b beneficial ownership report compliance discussion audit committee caption corporate governance board committee proxy statement material caption executive officer registrant report company policy business conduct cover employee include chief executive officer chief financial officer controller meet requirement sec rules promulgate section sarbanesoxley act policy business conduct available company web site wwwinvestorjnjcomgovernancepoliciescfm copy available shareholder charge write request secretary company principal executive office substantive amendment policy business conduct waiver policy grant chief executive officer chief financial officer controller post company web site wwwinvestorjnjcomgovernancecfm business day retain web site year addition company adopt code business conduct ethic member board director executive officer code business conduct ethic member board director executive officer available company web site wwwinvestorjnjcomgovernancepoliciescfm copy available shareholder charge write request secretary company principal executive office substantive amendment code waiver code grant member board director executive officer post company web site wwwinvestorjnjcomgovernancecfm business day retain web site year item executive compensation information call item incorporate reference material caption compensation discussion analysis executive director compensation compensation committee report proxy statement material incorporate reference material caption compensation committee report proxy statement shall deem furnish file report shall deem incorporate reference filing security act amend securities exchange act amend result furnish extent registrant specifically incorporate reference item security ownership certain beneficial owner management relate stockholder matter additional information call item incorporate reference material caption stock ownership section compliance proxy statement note common stock stock option plan stock compensation agreement note consolidated financial statement page annual report file exhibit report equity compensation plan information follow table provide certain information december concern share company common stock issue exist equity compensation plan table content number security weight average number security issue exercise exercise price remain available outstanding option outstanding option future issuance plan category warrant right warrant right equity compensation plan equity compensation plan approve security holder equity compensation plan approve security holder total include category follow equity compensation plan approve company shareholder stock option plan stock compensation plan longterm incentive plan include category share common stock company issuable equity compensation plan assume company acquisition follow company alza corporation scios inc innovasive devices inc inverness medical technology inc centocor inc share list issuable category issue plan approve shareholder company prior acquisition assumption plan company time acquisition option acquire equity acquire company replace option acquire common stock company stock option equity award type plan assumption plan company stock option equity award type plan future share include column issue plan approve shareholder applicable acquire company share issuable scio nonofficer stock option plan share issuable warrant inverness medical plan include category share common stock company issuable exercise outstanding stock option companys stock option plan nonemployee director column exclude share reflect column number security issue exercise outstanding option warrant right item certain relationship relate transaction director independence information call item incorporate reference material caption transaction relate person corporate governance director independence proxy statement item principal accountant fee service information call item incorporate reference material caption ratification appointment independent register public accounting firm proxy statement table content iv item exhibit financial statement schedule follow document file report financial statement follow audit consolidated financial statement note thereto material caption report independent register public accounting firm page annual report incorporate reference file exhibit report consolidated balance sheet end fiscal year consolidated statement earning fiscal year consolidated statement equity fiscal year consolidated statement cash flow fiscal year note consolidated financial statement report independent register public accounting firm financial statement schedule schedule ii valuation qualifying account schedule list omit require applicable exhibit require file item l regulation sk information call item incorporate reference exhibit index report table content johnson johnson subsidiaries schedule ii valuation qualifying account fiscal year end december december december dollar millions balance b alance begin end period accrual payment period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million million million december december december respectively include million adjustment relate previously estimate accrued sale reserve table content signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize date february johnson johnson registrant w c weldon w c weldon chairman board directors chief executive officer pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date w c weldon chairman board directors february w c weldon chief executive officer director principal executive officer c poon vice chairman board directors director february c poon j caruso chief financial officer principal financial officer february j caruso j cosgrove controller principal accounting officer february j cosgrove coleman director february coleman j g cullen director february j g cullen e johns director february e johns table content signature title date g langbo director february g langbo l lindquist director february l lindquist l f mullin director february l f mullin w perez director february w perez c prince director february c prince satcher director february satcher table content report independent register public accounting firm financial statement schedule board directors johnson johnson audits consolidated financial statement effectiveness internal control financial reporting refer report date february appear annual report shareholder johnson johnson report consolidated financial statement incorporate reference annual report include audit financial statement schedule list item opinion financial statement schedule present fairly material respect information set forth read conjunction relate consolidated financial statement pricewaterhousecooper llp pricewaterhousecooper llp new york new york february table content exhibit index reg sk exhibit table description item exhibit ai restate certificate incorporation date april incorporate reference exhibit registrant annual report year end december aii certificate amendment restate certificate incorporation company date incorporate reference exhibit registrant annual report year end january aiii certificate amendment restate certificate incorporation company date incorporate reference exhibit aiii registrant annual report year end december aiv certificate amendment restate certificate incorporation company effective incorporate reference exhibit registrant form q quarterly report quarter end july av certificate amendment restate certificate incorporation company effective april incorporate reference exhibit registrant form q quarterly report quarter end april b bylaw company amend effective february incorporate reference exhibit registrant form k current report file february request security exchange commission registrant furnish copy instrument define right holder long term debt registrant stock option plan nonemployee director incorporate reference exhibit registrant annual report year end december b stock option plan amend incorporate reference exhibit b registrant annual report year end december c stock option plan amend incorporate reference exhibit b registrant annual report year end january longterm incentive plan incorporate reference exhibit registrant registration statement file commission file e form stock option certificate restrict share nonemployee director certificate longterm incentive plan incorporate reference exhibit registrant form q quarterly report quarter end july f form restrict stock unit certificate longterm incentive plan incorporate reference exhibit registrant form q quarterly report quarter end october g executive bonus plan incorporate reference exhibit registrant form registration statement file commission november file h executive incentive plan amend incorporate reference exhibit f registrant annual report year end december domestic defer compensation certificate extra compensation plan amend incorporate reference exhibit g registrant annual report year end december j amendment certificate extra compensation plan effective january file document k defer fee plan nonemployee director amend incorporate reference exhibit h registrant annual report year end january table content reg sk exhibit table description item exhibit l amendment defer fee plan director effective january file document executive income deferral plan amend incorporate reference exhibit registrant annual report year end december n amendment executive income deferral plan effective january file document excess saving plan incorporate reference exhibit j registrant annual report year end december p amendments johnson johnson excess saving plan effective january file document q excess benefit plan supplemental retirement plan incorporate reference exhibit h registrant annual report year end january r amendments excess benefit plan johnson johnson affiliate company effective january file document executive life insurance plan incorporate reference exhibit registrant annual report year end january stock option gain deferral plan incorporate reference exhibit registrant annual report year end january u estate preservation plan incorporate reference exhibit n registrant annual report year end january v summary compensation arrangement name executive officer director file document w severance arrangement alex gorsky file document statement computation ratio earning fix charge file document page company annual report shareholder fiscal year portion annual report incorporate reference report deem file file document subsidiary file document consent independent register public accounting firm file document certification chief executive officer pursuant section sarbanesoxley act file document b certification chief financial officer pursuant section sarbanesoxley act file document certification chief executive officer pursuant section sarbanesoxley act furnish document b certification chief financial officer pursuant section sarbanesoxley act furnish document cautionary statement pursuant private security litigation reform act safe harbor forwardlooke statement file document management contract compensatory plan copy exhibit list provide charge shareholder submit write request specify desire exhibit secretary principal executive office company exj yexvwjhtm exj amendment certificate extra compensation plan exhibit j amendment certificate extra compensation plan effective january certificate extra compensation plan plan shall amend follow plan change plan shall rename certificate longterm compensation plan reference plan cec shall change clc section amendment follow new article seventeenth shall insert end plan seventeenth notwithstanding provision plan contrary term article seventeenth shall apply payment formula value employee share purpose plan term share shall mean clc share award vested december share article seventeenth intend ensure term plan comply section internal revenue code amend regulation guidance issue thereunder section payment share formula value employee share shall payable occurrence payment event subject limitation applicable specified employee set forth article seventeenth company shall pay formula value employee share single lump sum day period begin date payment event employee shall influence determination tax year payment b payment event purpose plan term payment event shall mean date follow occur respect employee date relate occurrence follow separation service mean treasury regulation section ah applicable rule section ii death iii disability mean section aac internal revenue code amend code regulation thereunder respect employee place longterm disability provide article company shall determine separation service occur respect employee base fact circumstance purpose establish time payment employee share company determination shall initially day date employee place longterm disability anniversary date c deferral payment employee elect defer receipt portion formula value hisher share receive amount form installment payment employee election defer receipt portion hisher cec holding pay installment pursuant provision article fourth seventh shall effective solely respect portion formula value employee clc share award vested january grandfathere share limitation applicable specified employee portion formula value specify employee share shall pay expiration sixmonth period specify code section aabi regulation thereunder delay shall affect payment portion formula value specify employee grandfathere share purpose plan specify employee shall mean key employee mean code section regard paragraph thereof high pay officer company applicable determination date pursuant procedure adopt company purpose identify specified employee article seventeenth compensation shall determine safe harbor definition set forth treasury regulation section dd shall exclude compensation permit treasury regulation section cgii e payment termination plan termination plan pursuant article sixteenth hereof respect employee termination arrangement sponsor company aggregated plan section company shall right sole discretion notwithstanding election employee pay formula value employee share lump sum extent permit section regulation guidance thereunder payment article seventeenth termination plan shall early thirteenth th month later twentyfourth th month termination plan company accelerate payment pursuant article seventeenth termination plan proximate downturn company financial health company exercise discretion accelerate payment article seventeenth company shall adopt new arrangement aggregated plan section year follow date plan termination f provision intend ensure compliance code section article seventeenth provision plan apply share include right company employee respect share shall limit term permit section term permit section shall automatically modify limited extent necessary comply section extent modification limitation permit section notwithstanding provision contrary effective october company discretion require permit elective basis change payment term applicable employee share accordance full extent permit applicable guidance section include limited irs notice propose treasury regulation section preamble section xic irs notice provide election december ii apply amount payable year election iii cause pay year election payable year g provision applicable grandfathere share article seventeenth shall event apply portion formula value employee grandfathere share amendment change plan change include exercise discretion respect grandfathere share october shall effective amendment change constitute material modification mean section acertification section amendment certain defer compensation plan johnson johnson company maintain certificate extra compensation plan executive income deferral plan defer fee plan director collectively plan compensation benefit committee board director company committee previously approve authorize certain amendment plan comply requirement section internal revenue code amend regulation guidance thereunder section nonmaterial change committee delegate management compensation committee mcc authority action necessary proper effectuate amendment plan approve authorize committee ii approve adopt amendment plan necessary comply change legal regulatory requirement apply plan resolve mcc certifie plan shall amend incorporate amendment attach hereto effective january specifically set forth resolve vice president human resource company consultation approval counsel authorize action discretion determine necessary appropriate incorporate attach amendment applicable plan ii ensure plan amend properly administer include limited make conform change plan andor restating plan entirety b adopt additional amendment plan necessary proper comply section c adopt andor amend administrative policy procedure plan date december management compensation committee johnson johnson w c weldon w c weldon title chairman j caruso j caruso title member k fostercheek k fostercheek title member c poon c poon title member exl yexvwlhtm exl amendment defer fee plan director exhibit l amendment defer fee plan director defer fee plan director plan shall amend inserting follow new section end plan effective january date specifically provide section requirement notwithstanding provision plan contrary effective january term section shall apply payment participant defer compensation account plan section intend ensure term plan comply section internal revenue code amend regulation guidance issue thereunder section payment account notwithstanding provision plan contrary effective january value participant defer compensation account shall payable solely single lump sum day period begin participant completion date date death early participant shall influence determination tax year payment b deferral payment effective january participant elect defer receipt portion defer compensation account receive amount form installment payment participant election defer receipt portion defer compensation account pay installment pursuant provision section shall null void january c provision intend ensure compliance section section provision plan apply deferral include right company participant respect deferral shall limit term permit section term permit section shall automatically modify limited extent necessary comply section extent modification limitation permit section payment termination plan termination plan pursuant section respect participant termination arrangement sponsor company aggregated plan section company shall right sole discretion pay participant value defer compensation account lump sum extent permit section payment section termination plan shall early thirteenth th month later twentyfourth th month termination plan company accelerate payment pursuant section termination plan proximate downturn company financial health company exercise discretion accelerate payment section company shall adopt new arrangement aggregated plan section year follow date plan terminationcertification section amendment certain defer compensation plan johnson johnson company maintain certificate extra compensation plan executive income deferral plan defer fee plan director collectively plan compensation benefit committee board director company committee previously approve authorize certain amendment plan comply requirement section internal revenue code amend regulation guidance thereunder section nonmaterial change committee delegate management compensation committee mcc authority action necessary proper effectuate amendment plan approve authorize committee ii approve adopt amendment plan necessary comply change legal regulatory requirement apply plan resolve mcc certifie plan shall amend incorporate amendment attach hereto effective january specifically set forth resolve vice president human resource company consultation approval counsel authorize action discretion determine necessary appropriate incorporate attach amendment applicable plan ii ensure plan amend properly administer include limited make conform change plan andor restating plan entirety b adopt additional amendment plan necessary proper comply section c adopt andor amend administrative policy procedure plan date december management compensation committee johnson johnson w c weldon w c w eldon title chairman j caruso j ruso title member k fostercheek k foster cheek title member c poon c p oon title member exn yexvwnhtm exn amendments executive income deferral plan exhibit n amendment executive income deferral plan executive income deferral plan plan shall amend insert follow new section end plan effective january date specifically provide section requirement notwithstanding provision plan contrary effective january term section shall apply deferral income elect january deferral payment amount section intend ensure term plan comply section internal revenue code amend regulation guidance issue thereunder section creation account effective january participant income deferral account shall divide separate account follow account shall consist deferral earning thereon ii grandfathere account shall consist deferred award credit participant income deferral account january grandfathere deferral specifically provide section reference plan income deferral account shall include account grandfathere account reference defer award shall include deferral grandfathere deferral b election deferral participant elect defer portion dividend equivalent payable company cec plan january effective january participant elect defer nonperformancebase compensation incentive payment dividend equivalent monie service perform taxable year provide election end taxable year precede year service render ii defer performance base compensation define treasury regulation section ae date month end performance period provide event election compensation readily ascertainable company shall establish procedure applicable form time deferral election accordance provision section b c payment account value participant account shall payable occurrence payment event company shall pay value participant account single lump sum soon practicable later expiration sixmonth period specify section aabi internal revenue code amend code regulations thereunder ii january year immediately follow year payment event participant shall influence determination tax year payment payment event purpose plan term payment event shall mean date follow occur respect participant date relate occurrence follow separation service mean treasury regulation section ah applicable rule section ii death iii disability mean code section aac regulation thereunder respect participant place longterm disability company shall determine separation service occur respect participant base fact circumstance purpose establish time payment participant account company determination shall initially day date participant place longterm disability anniversary date e deferral payment participant elect defer receipt portion account receive amount form installment payment participant election defer receipt portion income deferral account pay installment pursuant provision section shall effective solely respect participant grandfathere account shall event apply account f provision intend ensure compliance section section provision plan apply deferral account include right company participant respect deferral account shall limit term permit section term permit section shall automatically modify limited extent necessary comply section extent modification limitation permit section notwithstanding provision contrary effective october company discretion require permit elective basis change payment term applicable participant account accordance full extent permit applicable guidance section include limited irs notice propose treasury regulation section preamble section xic irs notice provide election december ii apply amount payable year election iii cause pay year election payable year g provision applicable grandfathere deferral grandfathere account section shall event apply portion participant grandfather deferral grandfathere account amendment change plan change include exercise discretion respect grandfathere deferral grandfathere account october shall effective amendment change constitute material modification mean section payment termination plan company terminate plan time amendment shall consent participant materially adversely affect right obligation respect defer award theretofore termination plan pursuant section respect participant termination arrangement sponsor company aggregated plan section company shall right sole discretion notwithstanding election participant pay participant value income deferral account lump sum extent permit section payment section termination plan shall early thirteenth th month later twentyfourth th month termination plan company accelerate payment pursuant section termination plan proximate downturn company financial health company exercise discretion accelerate payment section company shall adopt new arrangement aggregated plan section year follow date plan terminationcertification section amendment certain defer compensation plan johnson johnson company maintain certificate extra compensation plan executive income deferral plan defer fee plan director collectively plan compensation benefit committee board director company committee previously approve authorize certain amendment plan comply requirement section internal revenue code amend regulation guidance thereunder section nonmaterial change committee delegate management compensation committee mcc authority action necessary proper effectuate amendment plan approve authorize committee ii approve adopt amendment plan necessary comply change legal regulatory requirement apply plan resolve mcc certifie plan shall amend incorporate amendment attach hereto effective january specifically set forth resolve vice president human resource company consultation approval counsel authorize action discretion determine necessary appropriate incorporate attach amendment applicable plan ii ensure plan amend properly administer include limited make conform change plan andor restating plan entirety b adopt additional amendment plan necessary proper comply section c adopt andor amend administrative policy procedure plan date december management compensation committee johnson johnson w c weldon w c w eldon title chairman j caruso j ruso title member k fostercheek k foster cheek title member c poon c p oon title member exp yexvwphtm exp amendment johnson johnson excess saving plan exhibit p amendments johnson johnson excess saving plan effective january date specifically provide johnson johnson excess saving plan plan shall amend insert follow new addendum end plan addendum section requirement notwithstanding provision plan contrary effective january term addendum shall apply payment participant excess saving account addendum intend ensure term plan comply section internal revenue code amend regulation guidance issue thereunder section provision addendum section plan apply payment benefit january shall limit term permit section term plan permit section shall automatically modify limited extent necessary comply section extent modification limitation permit section payment event payment shall respect participant plan prior occurrence payment event purpose plan term payment event shall mean date follow occur respect participant date relate occurrence follow separation service mean treasury regulation section ah applicable rule section b death c disability mean code section aac regulation thereunder respect participant retire approve absence longterm disability define company longterm disability income plan company shall determine separation service occur respect participant base fact circumstance purpose establish time payment participant benefit plan company determination shall initially day date participant place longterm disability anniversary date payment excess saving account general occurrence payment event value participant excess saving account shall pay single lump sum day period begin date payment event event shall participant influence determination tax year payment section payment excess saving account grandfathere payment election notwithstanding provision plan contrary participant effective grandfathere payment election place payment event occur participant attain age value participant excess saving account shall pay form time elect participant purpose plan effective grandfathere payment election election participant defer receipt excess saving account andor receive payment excess saving account form installment payment submit december ii accordance plan rule procedure place time election include limited form time election iii month participant payment event payment commencement date participant excess saving account section shall day period begin date schedule payment pursuant participant effective grandfathere payment election event shall participant influence determination tax year payment section company shall sole discretionary authority determine participant effective grandfathere payment election include effective date election participant effective grandfathere payment election shall irrevocable december shall apply total value participant excess saving account death participant commencement benefit participant die excess saving account pay value participant excess saving account shall pay participant beneficiary soon practicable day period begin date participant death delay payment rule applicable specified employee shall apply payment account participant death deferral payment provide section addendum respect participant effective grandfathere payment election participant elect defer receipt portion benefit plan delay payment rule specify employee notwithstanding contrary portion specify employee excess saving account earn vested december earning thereon shall payable expiration sixmonth period specify code section aabi regulation thereunder purpose plan specify employee shall mean key employee mean code section regard paragraph thereof high pay officer company applicable determination date pursuant procedure adopt company purpose identify specify employee addendum compensation shall determine safe harbor definition set forth treasury regulation section dd shall exclude compensation permit treasury regulation section cgii pay specified employee sixmonth delay impose section addendum shall pay single lump sum participant seventh month participant payment event designate payment date payment shall treat designated payment date actually designated payment date later date calendar year designate payment date later th day calendar month follow designate payment date addition payment shall treat designated payment date day designate payment date notwithstanding forego participant shall way permit directly indirectly designate taxable year payment plan payment plan termination company terminate plan time termination plan respect participant termination arrangement sponsor company aggregated plan section company shall right sole discretion notwithstanding election participant pay participant value lump sum extent permit section payment section addendum termination plan shall early th month later th month termination plan company accelerate payment pursuant section addendum termination plan proximate downturn company financial health company exercise discretion accelerate payment section addendum company shall adopt new arrangement aggregated plan section year follow date plan terminationcertification section amendment certain employee benefit plan effective january date specify severance pay plan johnson johnson affiliate company excess benefit plan johnson johnson affiliated company johnson johnson excess saving plan benefit plan shall amend incorporate applicable amendment attach hereto date december pension committee johnson johnson k fostercheek k foster cheek title chair j caruso j ruso title member e dlugacz e dlu gacz title member j papa j p apa title member exr yexvwrhtm exr amendment excess benefit plan exhibit r amendment excess benefit plan johnson johnson affiliate company effective january date specifically provide excess benefit plan johnson johnson affiliate company plan shall amend insert follow new addendum end plan addendum section requirement notwithstanding provision plan contrary effective january term addendum shall apply payment participant benefit addendum intend ensure term plan comply section internal revenue code amend regulation guidance issue thereunder section provision addendum section plan apply payment benefit january shall limit term permit section term plan permit section shall automatically modify limited extent necessary comply section extent modification limitation permit section benefit effective january participant excess pension benefit shall split participant benefit participant grandfathere benefit follow benefit participant benefit shall equal participant total accrue benefit plan participant grandfathere benefit b grandfathere benefit participant grandfathere benefit shall portion participant benefit accrue earn vested december determine rule effect date payment event payment shall respect participant benefit plan prior occurrence payment event purpose plan term payment event shall mean date follow occur respect participant date relate occurrence follow separation service mean treasury regulation section ah applicable rule section b death c disability mean code section aac regulation thereunder respect participant retire approve absence longterm disability define company longterm disability income plan company shall determine separation service occur respect participant base fact circumstance purpose establish time payment participant benefit plan company determination shall initially day date participant place longterm disability anniversary date payment benefit occurrence payment event participant benefit shall pay participant pension commencement date purpose plan participant pension commencement date shall day month participant th birthday ii payment event whichever later time form payment participant grandfathere benefit shall govern term plan effect october form payment benefit elect participant pursuant applicable rule procedure plan participant benefit shall payable form single life annuity participant single payment commence form joint surviving spouse annuity participant marry distribution commence participant elect write manner times pursuant rule procedure company adopt receive benefit form payment available consolidated retirement plan johnson johnson qualified plan level income option provide election satisfie follow condition change form payment complie section treasury regulation section abii b payment participant benefit commenced date election c actuarially equivalent life annuity form elect participant schedule payment commencement date annuity pay absent election annuity determine company actuarially equivalent apply reasonable actuarial assumption method notwithstanding forego lump sum value participant total accrue benefit plan participant total benefit plan shall pay participant participant beneficiary event participant death single lump sum soon practicable day period commence participant payment event addition participant eligible receive portion benefit form lump sum payment portion benefit shall pay form lump sum participant pension commencement date remain portion benefit shall pay applicable annuity form accordance section death participant commencement benefit participant die pension commencement date benefit shall pay participant beneficiary commencing day month participant th birthday ii participant date death whichever later delay payment rule applicable specified employee shall apply payment account participant death deferral payment participant elect defer receipt portion benefit plan delay payment rule specify employee notwithstanding contrary portion specify employee benefit shall payable expiration sixmonth period specify code section aabi regulation thereunder purpose plan specify employee shall mean key employee mean code section regard paragraph thereof high pay officer company applicable determination date pursuant procedure adopt company purpose identify specify employee addendum compensation shall determine safe harbor definition set forth treasury regulation section dd shall exclude compensation permit treasury regulation section cgii pay specified employee sixmonth delay impose section addendum shall pay single lump sum participant seventh month participant payment event section addendum shall event apply participant grandfathere benefit designate payment date payment shall treat designated payment date actually designated payment date later date calendar year designate payment date later th day calendar month follow designate payment date addition payment shall treat designated payment date day designate payment date notwithstanding forego participant shall way permit directly indirectly designate taxable year payment plan payment plan termination company terminate plan time termination plan respect participant termination arrangement sponsor company aggregated plan section company shall right sole discretion notwithstanding election participant pay participant actuarially equivalent value excess pension benefit determine plan termination date lump sum extent permit section payment section addendum termination plan shall early th month later th month termination plan company accelerate payment pursuant section addendum termination plan proximate downturn company financial health company exercise discretion accelerate payment section addendum company shall adopt new arrangement aggregated plan section year follow date plan termination special transition election notwithstanding provision contrary effective october company discretion require permit elective basis change payment term applicable participant benefit accordance full extent permit applicable guidance section include limited irs notice propose treasury regulation section preamble section xic irs notice provide election december ii apply amount payable year election iii cause pay year election payable year particular respect participant eligible receive portion benefit form lump sum payment company discretion permit participant irrevocable election december receive portion lump sum payment pension commencement date payment election participant receive benefit lump sum payment section addendum shall irrevocable date submit accordance procedure establish company provision applicable grandfathere benefit specifically provide addendum shall event apply portion participant grandfathere benefit amendment change plan change include exercise discretion respect participant grandfathere benefit october shall effective amendment change constitute material modification mean section acertification section amendment certain employee benefit plan effective january date specify severance pay plan johnson johnson affiliate company excess benefit plan johnson johnson affiliated company johnson johnson excess saving plan benefit plan shall amend incorporate applicable amendment attach hereto date december pension committee johnson johnson k fostercheek k foster cheek title chair j caruso j ruso title member e dlugacz e dlu gacz title member j papa j p apa title member exv yexvwvhtm exv summary compensation arrangement exhibit v summary compensation arrangement name executive officer director compensation arrangement name executive officer follow description compensation arrangement approve compensation benefit committee board directors johnson johnson compensation committee february company chief executive officer chief financial officer highly compensate executive officer name executive officer annual base salary compensation committee approve follow base salary effective february name executive officer william c weldon chairmanceo dominic j caruso vice president finance cfo christine poon vice chairman worldwide chairman pharmaceuticals group russell c deyo vice president general counsel colleen goggin worldwide chairman consumer group retire march compensation committee recommend merit increase mr weldon base salary base strong performance mr weldon recommend compensation committee salary stay recognition current global economic environment compensation committee accepted approve mr weldon recommendation performance bonus compensation committee approve follow bonus performance payment performance pay form cash company common stock determined compensation committee mr weldon mr caruso ms poon mr deyo ms goggin stock option restrict share unit grant compensation committee approve follow stock option restrict share unit rsu grant companys longterm incentive plan lti plan stock option grant exercise price fair market value calculate average high low price company common stock new york stock exchange february option exercisable february expire february rsus vest february holder employ company date receive share company common stock rsumr weldon stock option rsus mr caruso stock option rsus mr deyo stock option rsus ms goggin stock option rsus nonequity incentive plan awards compensation committee approve follow nonequity incentive plan award recognition performance company certificate longterm compensation clc program know certificate extra compensation program award pay retirement termination employment end fiscal year clc value unit clc unit value vary time base performance company award clc unit grant executive officer year mr weldon clc units mr caruso clc units mr deyo clc unit ms goggin clc units equity compensation nonemployee directors nonemployee director receive nonretainer equity compensation quarter year lti plan form share restrict common stock fair market value grant date accordingly nonemployee director grant share restrict common stock lti plan february service board restrict share freely transferable february exw yexvwwhtm exw severance arrangement alex gorsky exhibit w kaye foster cheek executive committee member vice president human resources johnson johnson johnson johnson plaza new brunswick nj february mr alex gorsky worldwide chairman surgical care group executive committee member johnson johnson johnson johnson plaza new brunswick nj dear alex forgo shall reconfirm mutual understanding johnson johnson company term severance arrangement originally agree offer letter date january company terminate employment cause year february date rejoin company shall offer return execution general release severance payment determine accordance johnson johnson severance pay plan severance payment shall minimum equal year base salary addition company payment execution general release equal year base salary event resign company requirement relocate employment outside new jerseyeastern pennsylvania area year february consent payment pursuant letter agreement shall subject mitigation right setoff shall subject appropriate taxis withholding acceptance letter agreement forego replace supercede previous agreement write oral term severance arrangement signify acceptance term letter agreement sign copy letter agreement return question concern letter agreement feel free sincerely kaye fostercheek kaye fostercheek executive committee member vice president human resource cc ullmann l uthgenannt ng alex gorsky february agree accept alex gorsky february signature date ex yexvhtm ex statement computation ratio earning fix charge exhibit johnson johnson subsidiaries statement computation ratio earning fix charge dollar million fiscal year end december december december january january determination earning earning provision taxis income fix charge total earning define fix charge rent interest expense capitalization interest total fix charge ratio earning fix charge ratio earning fix charge compute divide sum earning p rovision taxis income fix charge fix charge fix charge r epresent interest expense interest capitalize amortization debt discount appropriate interest factor operating lease ex yexvhtm ex page company annual report shareholder exhibit table content management discussion analysis audit consolidated financial statement organization business segment consolidate balance sheet result operation consolidated statement earning analysis sale business segment consolidate statement equity analysis consolidate earning provision taxis income consolidate statement cash flow liquidity capital resource note consolidated financial statement information report independent register public accounting firm cautionary factor affect future result management report internal control financial reporting summary operation statistical data shareholder return performance graph johnson johnson annual report management discussion analysis result operation financial condition organization business segment management objective primary objective company achieve superior level description company business segment capital efficient profitable growth accomplish company johnson johnson subsidiaries company management operate business consistent certain strategic approximately employee worldwide engage principle prove successful time end research development manufacture sale broad range company participate growth area human health care product health care field company conduct business commit attain leadership position growth area virtually country world primary focus development innovative product service new product relate human health wellbeing product introduce past year account company organize business segment approximately sale billion consumer pharmaceutical medical device diagnostic sale invest research development consistent consumer segment include broad range product investment reflect management commitment baby care skin care oral care wound care women health importance ongoing development new differentiate care field nutritional overthecounter pharmaceutical product service sustain longterm growth product product market general public operating company locate country sell distributor directly independent chain retail company view principle decentralize management outlet world pharmaceutical segment include asset fundamental success broadly base business product follow therapeutic area antiinfective foster entrepreneurial spirit combine extensive antipsychotic cardiovascular contraceptive dermatology resource large organization ability react quickly gastrointestinal hematology immunology neurology oncology pain local market change challenge management urology virology product distribute company commit develop global business leader directly retailer wholesaler health care professional drive growth objective business manage prescription use medical device diagnostic segment longterm order sustain leadership position achieve growth include broad range product principally provide endure source value shareholder professional field physician nurse therapist hospital unify management team company dedicated diagnostic laboratory clinic product include cordis employee achieve objective credo credo circulatory disease management product depuy orthopaedic joint provide common set value serve constant reminder reconstruction spinal care sport medicine product ethicon company responsibility customer employee surgical care women health product ethicon endosurgerys communities shareholder company believe minimally invasive surgical product lifescan blood glucose basic principle overall mission improve quality monitor insulin delivery product orthoclinical diagnostic life people enable johnson johnson professional diagnostic product vistakon disposable contact continue leader health care industry lense company structure base principle decentralize management executive committee johnson result operations johnson principal management group responsible analysis consolidate sale operation allocation resource company worldwide sale increase billion compare committee oversee coordinate activitie consumer increase sale pharmaceutical medical device diagnostic business increase consist follow segment product line company compete company sale increase local global locate world competition volume exist product line regard number size price compete company involve competition research involve currency development improvement new exist product total process particularly significant development new innovative product important company success sale company billion billion area business include protect company billion represent decrease portfolio intellectual property competitive environment increase require substantial investment continue research sale respectively sale international company billion force addition development maintenance customer billion billion represent demand company consumer product involve significant increase expenditure advertising promotion johnson johnson annual reportthe fiveyear compound annual growth rate worldwide international sale respectively analysis sale business tenyear compound annual growth rate worldwide segment international sale respectively consumer segment consumer segment sale billion increase change operational growth remain positive currency fluctuation international geographic region experience sale growth consumer segment sale billion increase consist europe western international sale billion increase hemisphere exclude asiapacific result operation currency fluctuation africa region sale increase include impact currency fluctuation dollar foreign currency overthecounter otc pharmaceutical nutritional positive impact europe western franchise sale billion increase hemisphere exclude asiapacific africa primary contributor growth successful launch region overthecounter zyrtec allergy product line company customer company announce voluntary labeling change children represent total consolidated revenue cough cold medicine usage child age year encourage safe effective use product action significant impact sale otc pharmaceutical nutritional franchise skin care franchise sale grow billion sale growth primarily aveeno clean clear neutrogena johnson adult product line new product relate acquisition beijing dabao cosmetics co ltd baby care franchise sale grow billion growth primarily international market product line women health franchise sale grow billion primarily successful launch new product oral care franchise sale grow billion sale growth drive performance listerine mouthwash product line consumer segment sale billion increase change operational growth remain positive currency fluctuation consumer segment sale billion increase international sale billion increase result operation currency fluctuation acquisition pfizer inc consumer healthcare business net relate divestiture increase total sale growth operational growth total consumer segment major consumer franchise sale change dollar million vs vs otc pharmaceutical nutritional skin care baby care womens health oral care wound careother total management discussion analysis result operation financial condition oral patent result significant reduction sale p p p c u r c j p e l c f r p u c e wn n n n n n n r ee u f n l c n e xeh oh h r ur e ic c c c c c r v ts mo rh l c l f n p da hua ra r e r r r e li er p rm p p e uc ole h e e e sn r r u er r pr e sp ba rr mo ir aa de ir m pa n cc yi os tv itc ng u rm ut f es mrm p ro ei nie n ri e ta de ut pec v n aa hve e e e e mar cina yn gal idc c aca aa ti wa n ed e nri ni ec e toe ae e c e sd toms w tt x x tv eri rda e c n r u u oa e cn xu e c f rp ce e h nan ott k p eie rf nd f c h rh e fo td eu l ea w fi boo ga x n hc c l l e l w ai ur r tt h et stt e w e eft f e rt uaa ts ho ea eo ts sio e c c e h le pp eui hn h l g sl l e pc h e hp x n x l e x ee r ev aet cs r er sh mya eh ta u ef ti r e ii sa u toe e vw os za r p bf te n ii e p l sa l q ul n til m og g r u rn un op g e e ir p f ip cw n tf pm wp ss k v se n f ei r ls l ri cp r ei v nl n m u g h pio hy e e ro rx fi w r l ee v ee e e et e r u nis li eh rr n n n e m n atd u io rm chg tn n onn r e g b tei n e c ri ri ba e gt p na ye nu b l iost n sia mt f ai nai aa nem tc dv l eb c r er dv e ii ag lls n ei l w il j rtt l dn ch k il lib se oh fa alpe oe aie n p l ia n unma g ed e sp ai n ico car l rn hi n leil l l ai lgn n ni th iim ee e nen se e abp es nk hy e st va b c gme ti n wa ts pcu tie p er e g rn gea p e pi p ep l eo n ct e n e er sut br h l c ao w ga rr ei oy da l ih au nn fur h mw yc d iu ni hn r r ir eec n xa lc ec n c u n ea te g p ad ms e e na g l ohst ps lo r e l al ar ru e p e p tt k sn n l es l g rh sm gsrh il tge f x ed zi ie f te ia e w uti le ia f e ir w es r p c c nv ai e n e ac sgl aw mxt p e ed n ch u e ga twn g gu ne uh r nd om ra dp aw n p e si x ir bt r r tl blce se tefp np uh nil tr sa p amh tear orle e ns e e ho iy c e ip eei aa pl e w u sr c rn l n wn e f e gl sso tn e ar fb si c e th r hm not f en ec r n n xrr erc ei lah f x h ao es l f ii te v ey pd tf diiy l hnna ood p yn cns hsai e tw p e sw eo e xis e l r b f r hf oo e ap iatul cs r e idl k e nn rt rtl e gu tih e et mf tu h nh rp n iu bm l ohe h r uh x e e ls inc ef bic e tr e n efet e dp ae pa n r r n p dw ce lf eu p sf g b er ee nu k cf u bt v p p ms p ed e fco v aa r r ie ii x cr g e ie sn sl rn ir ah lme ril tt p ln tr l se ise ot dei rd cd st si f g ttra weo nec h aa ya eo n hn ri wb uua p ea al n r k tn fe n lnn c e e u ne se en h ho arh eg sg e rr r p os ii hi ts r c sgra sd ee er l h snt scr cr la ay eih faf io ac l da eg oa h oa cru sebdpw ld e d onn ut nd emi r dc ai fr v ft abe fu ct ct sj st eo ve e os uh h p lct iic te r e c e al n e ef dr f k wn r f l tr n ai r ti hne eo p ct r egn iot r tet ea tn nr dh siod divs nf gee rr h f r h c r u h f pn nn h r r n h oe f ee e e f r e r e ea l p co ic e r e e rl e p es v v c al c u h n l p rf lr c l ti l r se r vn ee p l r not p r lh p le al io n te e c e ha es n u ra h oi sc e c b b de p u e h ns eo ct e v en lv e r uin r u r ie e ei g nn aen ai et p el l ttp e e rt h e e ys n al l eh p l tt e r n n cnh di aa gfi e rac ro l pp e e x g lb e l au q yaw n nl eo ot tpu n tn n ir ta e anr r n ia n c lo og h fe c not q sf p aul g e u ai ds aa kt r g f fr ed os nu ms rn nc op g r n ea npl l hn e n n et n ao eh ea ae u toe w w ats v nd rn pn d ha f n ur rl n e n p v dc na ret n gde n n pi pg c n pe en h e lb gi ah e yl f tn r r ri w te rr ri g r att u l io e p te te l h p r e w e ng h e h ec r ne apco ah w f sc n rm e del v ds eo f v e de e da li n ta ao ya th e ut ci ner l uyp r r e cn h uy lc p cn sc e c ol b v af m aa co c ra f n st f hb rh tay e l op oi d r th f p mgi ol si r ur oyo ps yn ih l ei tr r mr p tt eu nyi yez f mx e pa hea e l nr ag pe ac ss en e tel h ce abn ia g ep p ic e lbn et cer g er n n poa e eap e h ip cr lee ec c e p ah ae tel te vd c lu uaei e f h cp r ee v ta ph vr nen nn ne ns oen l pu u r r c e ri e r yt utt ui rs rr sm ee r ut e sy p de e der vn ih l ns l v f trd n z nd e r v c ntp c h np ye ss e sg pa ad ee e naoo c l ai aiea e u ta ea eip l ni c vr ar gor lf oa f c r pd et la vs e rs es v l e n e cl ge er rnl u e sl e p sde n ei ee c xe ec r r r ms e f ar vr r ei h oc lip rd fza c enod dv ttd b n nf li osd l eo n nw po cga v e h ce r mio eal e v iao r pls v nn c trr et ot si yb n c ai mn e r rh mle ia ec hs ar tbd n ou l tn n e c ly r e lyc da u wv e ul n isr h sb e e r n c aa ntgw e ah ra ew e sa z ntai et er g n u e hyf ev e co sa e fd oi e e da rp ime tr u ts ea l ee p e n e xe ro l f ev l df ex eh p pr nf c l oek tas dr r p xe cl p e d eax r oo ro ioe fa ad r u nao f b ps na ddm u rnm ut ofn l r pt r p nb u e ct x ee e ea e e rc uu rrg c c dn u iip md vs od n l r rnm lco ea e ta trk li n e pt ica ie not ehi ea e sc n p oa n b r e n c pn tu gf lac f bh e p nel e b n tt eo e vv rt rl b rct e e n l pe tdi rr ig tar ie ow pe inl b w ne ir ei ho l dl l rs n wd fy r b si p r drt v tg u yo ao eo n eh iti e wao u ele te uo ea vv en tr w u htfe ri r n iida r cr sron r n av ae n b oau ah r e h f tl rtj ie l rr h n dsi ase h nv g le bn tw fel e te h er ia h l pc en niw h c ti l h ray wae op eo e rltt e ar p aee hah ftrat dr n e fr irt h tm ss te tfi ibe p teh dd r ano c hi h e e li ml r nd ie vln u fe ho gr ee naf n oo oi c tefen f er res n r dt l rt decline billion market exclusivity risperdal oral expire june loss market exclusivity risperdal major pharmaceutical product revenue change dollar million vs vs remicade infliximab topamax topiramate procriteprex epoetin alfa risperdal risperidone levaquinfloxin levofloxacinofloxacin risperdal consta risperidone concerta methylphenidate hcl aciphexpariet rabeprazole sodium duragesicfentanyl transdermal fentanyl transdermal system total prior year amount reclassify conform current presentation johnson johnson annual reportand prezista oncedaily dose hiv combination technology additional contributor growth therapy treatmentnave adult traditional approval twice realize gastric band endoscopy product outside daily dose use treatmentexperience adult patient outside european commission grant approval ethicon franchise achieve sale billion prezista combination ritonavir antiretroviral increase prior year result growth medicinal product treatment hiv infection extend hemostasis mesh biosurgical product line indication include treatmentexperience adult patient sale cordis franchise billion decline company submit application regulatory approval decline reflect low sale cypher additional compound golimumab monthly sirolimuselute coronary stent increase global competition subcutaneous treatment adult active form rheumatoid decline partially offset performance biosense arthritis psoriatic arthritis ankylose spondylitis file webster neurovascular business european union filing submit diabetes care franchise achieve sale billion rivaroxaban oral oncedaily anticoagulant prevention increase prior year growth drive deep vein thrombosis dvt pulmonary embolism pe sale animas business new product launch sale patient undergo hip knee replacement surgery carisbamate growth ultra product line outside adjunctive treatment partialonset seizure patient vision care franchise achieve sale billion year age old trabectedin know yondelis increase prior year sale acuvue oasys outside administer combination doxil day acuvue moist acuvue oasys doxorubicin hcl liposome injection treatment woman astigmatism major contributor growth relapse ovarian cancer orthoclinical diagnostic franchise achieve sale pharmaceutical segment sale billion billion increase prior year result increase change growth immunohematology immunodiagnostic product operational growth remain increase relate medical device diagnostic segment achieve sale positive impact currency fluctuation pharmaceutical billion represent increase prior year segment sale billion increase international operational growth positive pharmaceutical segment sale billion increase impact currency fluctuation sale billion include operational growth relate increase international sale billion increase positive impact currency fluctuation operation positive currency impact medical device diagnostic segment medical device diagnostic segment achieve sale analysis consolidate earning billion represent increase prior year operational growth positive provision taxis income om n n f f n r fec ip v ndr p et ta e e e k u kh hc n w n ye ei st n lb e p yf e cd er e r l e e r h tm npw r hf p ust r ch e nou tc omh e cdyu hn p h u er f aar er c ed v e dt ne n cn di l mdr pc ic ni n nc oy p rh oe efe c r ri j sf r sr ni dl po en u em uu irr n aa ac c cra ytt gd diu c eeo r sedp uea h tr aie cct ei yrai e v ntoo r c l v f e dlnn hn ris et n ra ss h naa e not p h oll r n le c r eu u ys lc os h g u gs n ra rlw n sie n yo e n yete w rn ews b r eab oa ae u ph ra cupfl r le r h tr w ip es n ti n eo dd e hw g u vs u ei ce st cpi db r tv ts gbe r rt ie hl l es ri ml u l oi ei nl oc n u ei wa l gnu c en gr n tt r l sc oi r hhui l r h e oa ow w e hn fb n fn ec u h g l si el si n mc uh tm n tor ce h ae ap cb e iaa hn ea nilsn l sc lp ye st n c l tn n h ht f n nio c e p ag n r e tae n f rta c ob b h cio os e lb el l ni oe l l b ni il w will wd la tgi el n ne l rt tba ib ie oo hn r ii neey lnd h n l gse n l ag ra ne lh la r w e cn gf wer h e non e hr e n r ri b n c w ni w tn g ol ei hcl fi r nd eo sp ttb sh n emb r si el e wl e li g c na oe n f n arr w fe ts v ic tpn e cm ep r r dro vo r n n ed eto f es ut riv aht c b aver sh csii reei rab uo ol e nl l ri ru si mo eo ic rt n n e h sn dt pn gu ct u rg sa r ro tn u iee ne n nr b c r ea et e nsua fnt e torx h c irf sg nie e e rn e io ev n obs g ea r f l pr e cls u r hn h c apc b e vti si n un rb l cm sg tl rc e ii e ho iol eo hn op l n n ti afn eg n g n nn r oc ie sc gfe b oh n f ehi ed ln ra e c r tr h ar igo oe nxi se eg v not esh seh ss ae e reoe srf consolidate earning provision taxis income major medical device diagnostic franchise sale change dollar million vs vs depuy ethicon endosurgery ethicon cordis diabetes care vision care orthoclinical diagnostic total prior year amount reclassify conform current presentation management discussion analysis result operation financial condition cost product sell sell marketing administrative great proportion sale attributable consumer expense cost product sell sell marketing segment high selling marketing administrative administrative expense percent sale follow spend additionally company utilize gain associate divestiture professional wound care sale business ethicon inc fund increase investment spending cost product sell partially offset ongoing cost containment effort percent point increase prior year increase percent sale cost sell marketing administrative product sell primarily impact newly acquire consumer expense brand increase percent sale selling percent point increasedecrease marketing administrative expense primarily prior year impact newly acquire consumer brand partially offset cost containment effort cost product sell percent sale remain flat increase percent sale cost prior year change mix business high sale product sell unfavorable product mix high growth consumer business slight sale decline manufacturing cost pharmaceutical consumer segment pharmaceutical business continue negative impact decrease percent sale sell marketing cost product sell percent sale offset administrative expense result leverage manufacturing efficiency nonrecurre positive item sell expense reduction advertising promotional negative item increase spending percent sale sell marketing administrative expense primarily change mix business research development expense exclude inprocess research development charge segment business follow dollar million sale sale sale consumer pharmaceutical medical device diagnostic total research development expense percent decreaseincrease prior year research development research development activity fully integrate biopharmaceutical company develop represent significant company business market biosurgical immunotherapy product account expenditure relate development new product million tax iprd charge improvement exist product technical support product company record charge iprd compliance governmental regulation protection million tax relate acquisition conor consumer patient medsystem inc iprd charge include operating reduction pharmaceutical research profit medical device diagnostic segment development spending primarily increase efficiency company record iprd charge million pharmaceutical research development activity tax relate acquisition consumer healthcare business pfizer inc vascular control systems inc ensure restructure company achieve approximately medical inc colbar lifescience ltd hand innovation llc billion annual cost saving outline restructure future medical system sa charge relate consumer program announce note consolidated healthcare business acquire pfizer inc account financial statement additional detail relate restructuring million tax iprd charge include inprocess research development company operate profit consumer segment iprd charge record charge inprocess research development iprd follow acquisition include operate profit million tax relate acquisition amic medical device diagnostic segment vascular control ab surgrx inc healthmedia inc omrix biopharmaceuticals systems inc privately hold company focus develop inc healthmedia inc privately hold company create web medical device treat fibroid control bleed obstetric base behavior change intervention account million gynecologic application account million tax tax iprd charge include operate profit iprd charge ensure medical inc privately hold company consumer segment iprd charge follow develop device postcatheterization closure femoral acquisition include operate profit medical artery account million tax iprd charge device diagnostic segment amic ab swedish developer colbar lifescience ltd privately hold company specialize vitro diagnostic technology use pointofcare near reconstructive medicine tissue engineering account patient setting outside physical facility clinical million tax iprd charge hand innovation llc laboratory account million tax iprd privately hold manufacturer fracture fixation product charge surgrx inc privately hold developer advanced upper extremity account million tax iprd bipolar tissue sealing system enseal family device charge future medical system sa privately hold company account million tax iprd charge omrix biopharmaceutical inc johnson johnson annual reportprimarily develop manufacture market arthroscopic fluid consumer healthcare business pfizer inc integration management system account million tax record iprd charge pharmaceutical segment pharmaceutical segment income expense net income expense net operating profit increase percent sale include gain loss relate sale writedown operate profit increase primary driver certain investment equity security hold johnson johnson improve operating profit restructuring charge development corporation gain loss disposal million million natrecor intangible asset property plant equipment currency gain loss minority writedown record pharmaceutical segment interest litigation settlement liabilitie royalty income operating profit decrease percent sale favorable change billion income expense net operating profit decrease result million primarily increase income net restructuring charge million natrecor litigation settlement award billion gain billion intangible asset writedown divestiture professional wound care business ethicon inc natrecor intangible asset write medical device diagnostic segment operate billion profit medical device diagnostic segment increase income expense net include charge percent sale operate profit million tax relate natrecor intangible asset increase improved operating profit result writedown gain million associate guidant million gain net litigation settlement favorable product acquisition agreement termination fee associate expense mix manufacturing efficiency low iprd charge include addition include expense million versus million additionally associate record additional product liability reserve million restructuring charge record integration cost associate acquisition operating profit medical device diagnostic segment consumer healthcare business pfizer inc decrease percent sale operating profit decrease result million iprd charge million restructuring charge p pe err aa tit ni gn pg r op fr itso bf yit b ey g ms ee ng tm oe f n ess r e foll w g r e e mmnc ie lll n iu otd n te ed rm th ine g tia oi nn fa es es leci sa st e ad sw oit ch ia th ee g exu pid ea nn st e sc q ou fisition percent segment sale interest income expense interest income decrease dollar millions million low rate interest earn despite high consumer average cash balance cash balance include marketable pharmaceutical security billion end average med device diagnostic billion compare billion average cash balance total increase average cash balance primarily expense allocate cash generate operating activity segment interest expense increase million earning provision high debt balance second half company taxis income convert shortterm debt fix longterm debt high interest rate net debt balance end note consolidated financial statement detail billion compare billion end amount allocate segment include interest income expense minority interest high debt balance primarily purchase general corporate income expense company common stock ongoing common stock repurchase program announce july fund acquisition interest income decrease million low consumer segment consumer segment operating profit average cash balance decline average cash balance increase percent sale operate primarily acquisition consumer healthcare profit increase cost synergy low integration cost business pfizer inc december relate acquisition consumer healthcare business interest expense increase million compare pfizer inc cost containment initiative contribute prior year high average debt balance net debt increase operating profit consumer segment operating balance end billion compare profit increase acquisition cost billion end high debt balance associate consumer healthcare business pfizer inc debt associate acquisition consumer percent sale operating profit increase healthcare business pfizer inc common stock iprd expense million expense repurchase program announce associate interest income increase million primarily high rate interest high average cash balance despite billion common stock repurchase program increase acquisition activity compare prior year interest expense increase slightly compare high average debt balance billion billion partially offset decrease interest rate management discussion analysis result operation financial condition provision taxis income worldwide effective income tax company hedge exposure fluctuation currency rate exchange rate effect certain asset liabilitie tax rate increase compare increase foreign currency enter currency swap contract taxable income high tax jurisdiction relative taxable income change spread foreign interest rate low jurisdiction addition tax rate benefit company interest rate sensitive financial instrument onetime gain million relate business restructure increase decrease unrealized value company swap certain international subsidiary increase taxable contract approximately million scenario maturity income low tax jurisdiction relative taxable income high gain loss swap contract offset gain tax jurisdiction low international tax rate certain country loss underlie transaction compare prior year impact future cash flow company enter financial instrument trading liquidity capital resource speculative purpose company policy enter contract party liquidity cash flow equivalent credit rating counterpartie contract cash cash equivalent billion end major financial institution significant concentration compare billion end primary source exposure counterparty management believe risk cash contribute billion increase versus prior year loss remote billion cash generate operating activity company access substantial source fund billion net proceed long shortterm debt major numerous bank worldwide september company use cash capital spend billion acquisition secure new day year credit facility total credit billion dividend shareholder billion available company approximate billion repurchase common stock net proceed exercise billion expire september billion expire option billion september interest charge borrowing credit cash flow operation billion result line agreement base bid provide bank prime billion net earning billion noncash charge rate london interbank offer rate libor plus applicable relate depreciation amortization stock base compensation margin commitment fee agreement material billion iprd offset increase work capital total borrowing end billion billion net use relate change asset liability billion respectively increase borrowing net effect acquisition billion result finance general corporate purpose company continue access liquidity continuation common stock repurchase program commercial paper market additional detail announce net cash cash current marketable borrowing note consolidated financial statement security net debt billion compare net debt company anticipate operate cash flow exist credit billion total debt represent total capital facility access commercial paper market provide shareholder equity total debt total sufficient resource fund operating need capital shareholder equity share end compare yearend increase johnson johnson continue industrial company triple credit rating access credit financing market risk commercially favorable term summary borrowing company use financial instrument manage impact find note consolidated financial statement foreign exchange rate change cash flow accordingly company enter forward foreign exchange contract protect contractual obligation commitment value certain foreign currency asset liability company contractual obligation primarily lease debt hedge future foreign currency product cost gain loss unfunded retirement plan significant obligation contract offset gain loss underlie satisfy obligation company use cash operation transaction appreciation dollar follow table summarize company contractual december market rate increase unrealized obligation aggregate maturity december value company forward contract million note consolidated financial statement conversely depreciation dollar detail december market rate decrease unrealized value company forward contract million unfunded scenario gain loss forward contract offset operate debt retirement gain loss underlie transaction dollar million lease obligation plan total impact future earning cash flow total amount include interest expense tax matter note consolidated financial statement johnson johnson annual reportshare repurchase dividend sale return generally estimate record base july company announce board director historical sale return information product exhibit unusual approve stock repurchase program authorize company sale return pattern date competition marketing buy billion company common stock matter specifically investigate analyze repurchase program time limit suspend accounting sale return accrual period discontinue time share acquire sale return allowance represent reserve product available general corporate purpose company fund return expiration destruction field share repurchase program combination available cash specific area product recall return reserve base debt december company repurchase historical return trend product market percent aggregate million share johnson johnson common gross sale stock current repurchase program cost billion promotional program product list allowance addition company annual program repurchase cooperative advertising arrangement record year share use employee stock incentive plan incur continue promotional program include coupon company increase dividend th volumebase sale incentive program redemption cost consecutive year cash dividend pay share consumer coupon base historical redemption experience compare dividend share product value volumebase incentive program base share dividend distribute follow estimate sale volume incentive period record product sell company earn service revenue co promotion certain product include sale customer quarter promotional arrangement evaluate determine second quarter appropriate amount defer quarter addition company enter collaboration arrangement fourth quarter contain multiple revenue generating activity revenue total arrangement recognize activity perform deliver base relative fair value upfront fee receive january board director declare regular cash arrangement defer recognize revenue dividend share payable march earn obligation period shareholder record february company reasonably likely change assumption calculate expect continue practice pay regular cash dividend accrual rebate return promotion anticipate material effect financial statement company currently disclose impact change assumption information quarterly annual filing material financial critical accounting policy estimate statement impact management discussion analysis result operation table progression accrue rebate financial condition base company consolidate return promotion reserve doubtful account reserve financial statement prepare accordance cash discount segment business fiscal year end accounting principle generally accept preparation december december financial statement require management estimate assumption affect amount report consumer segment revenue expense asset liability relate disclosure actual result differ estimate balance balance company believe understand certain key accounting beginning payment end policy estimate essential achieve insight dollar million period accrual period company operating result financial condition key accounting policy include revenue recognition income taxis legal accrue rebate selfinsurance contingency valuation longlive asset accrue return assumption determine amount record pension accrue promotion employee benefit plan account stock option subtotal revenue recognition company recognize revenue reserve doubtful product sale good ship deliver title risk account loss pass customer provision certain rebate sale reserve cash incentive trade promotion coupon product return discount discount customer account reduction sale total period relate sale record product discount grant base term accrue rebate arrangement direct indirect market participant accrue return market condition include price charge competitor accrue promotion rebate large medicaid rebate provision subtotal e not aim lya sit se nb da pe rod j eo cn ec n mtr aa rc kt eu ta cl ote nr dm io nh sis r ti hc ea l v e ax rip oe ur sie mnc ae rk etr te snd reserve doubtful serve company evaluate market condition product account group product primarily analysis wholesaler reserve cash thirdparty sellthrough market research datum discount internally generate information total include reserve customer rebate million december million december record contra asset management discussion analysis result operation financial condition effect company result operation cash flow financial p harmaceutical seg man p ii nti n company adopt fasb interpretation fin balance balance accounting uncertainty income taxis interpretation dollar millions b oe fg pin en ri og ccrual paym oe tn ht es r pee rin od fasb statement interpretation prescribe recognition threshold measurement attribute financial statement accrue rebate recognition measurement tax position take expect accrue return take tax return interpretation provide guidance accrue promotion derecognition classification matter note ru eb seto rt va el doubtful c n c n deli ed ta x ete e md b f ei rn n c l ta eat nm e dn et cs e f mor b f eu rr h e r f rm ta ht eio cn u r meg ua lar td ivin eg account amount undistributed international earning approximately reserve cash billion billion respectively company intend discount continue reinv undistributed international earning expand total international operation tax expense record respect undistribute portion intend accrue rebate repatriation accrue return legal self insurance contingency company record accrue promotion accrual contingency include legal proceeding subtotal product liability case arise normal course reserve doubtful business accrual base management judgment account probability loss applicable actuarially reserve cash determine estimate additionally company record insurance discount receivable amount thirdparty insurer recovery total probable appropriate reserve receivables record estimate amount collect include reserve customer rebate million december party insurer million december record contra asset include million adjustment relate previously estimate accrued sale reserve longlive intangible asset company assess change economic condition make assumption medical device diagnostic segment estimate future cash flow evaluate value company property plant equipment goodwill intangible asset balance balance assumption estimate change time begin payment end necessary company record impairment dollar million period accrual period charge accrue rebate employee benefit plan company sponsor accrue return retirement pension plan include define benefit define accrue promotion contribution termination indemnity plan cover employee worldwide plan base assumption subtotal discount rate expect return plan asset expect salary reserve doubtful increase health care cost trend rate note account consolidated financial statement detail rate reserve cash effect rate change companys result discount operation total stock option fiscal quarter company adopt statement financial accounting standard accrue rebate sfas r share base payment company accrue return apply modify retrospective transition method implement accrue promotion sfas r previously report financial statement subtotal restate accordance provision sfas r reserve doubtful note information stock option account new accounting pronouncement reserve cash refer note consolidated financial statement recently discount adopt accounting pronouncement recently issue accounting total pronouncement adopt december include reserve customer rebate million december million december record contra asset include million adjustment relate previously estimate sale rebate reserve company earn service revenue copromotion certain product year present service revenue total revenue include sale customer income taxis income taxis record base amount refundable payable current year include result difference gaap accounting tax reporting record defer tax asset liability company estimate defer tax asset liability base current tax regulation rate change tax law rate affect record defer tax asset liability future management believe change estimate material johnson johnson annual reportreporte period matter e w b cauc h h rseo e ei r n n c e e io ns fm reep ric ssa p n ha oy r n veid ss e et ha e taw oxa n pa r rr hak ee e e st sh et eea c f cat ct nc e c np eo p cr ro e nr l r sis ncu syc ht eba ok cr e ue su hs p c ee ao nrn ysi sn iu hn agn e c e aorsn l v ota nonro gfd n hm eae ln tht f inl oi g f w n rsi mef ic f e aoa tr n ot ot h n tam e rt e p p ga e ac r rtit d ntn h g et h l ece g oc lo pm rl op d en eey ds n fr ge ss u nlt cs ao lf tp ae tera mti eo nn ts fon rd f uca rt hh er stand policy pricing product responsibly period united states weight average compound annual common stock market price growth rate company net price increase health care company common stock list new york stock product prescription overthecounter drug hospital exchange symbol jnj composite market price range professional product consumer price index johnson johnson common stock c p ini f lation rate continue effect worldwide economy inn cd ac ns ge cq ou se tn st l th eo n c oh pw aa ny c trm ivp ea sn ti oe ap ine tr aa inte sin p rh oe fi tf mc ae r ns quarter h g h l ow h g h l ow cost reduction program productivity improvement second quarter periodic price increase quarter company expose fluctuation currency exchange fourth quarter rate change value dollar compare yearend close foreign currency company sale income expense increase decrease translation cautionary factor affect foreign sale million income million company face worldwide health care change future result continue result pricing pressure include health care annual report contain forwardlooke statement forward cost containment government legislation relate sale look statement relate strictly historical current fact promotion reimbursement anticipate result base management plan subject change behavior spend pattern purchaser uncertainty forwardlooke statement identify health care product service include delay medical use word plan expect anticipate procedure ration prescription medication reduce estimate word similar meaning conjunction frequency physician visit forego health care insurance thing discussion future operation financial coverage result current global economic downturn performance company strategy growth product continue impact company business development regulatory approval market position expenditure company operate environment forwardlooke statement base current expectation increasingly hostile intellectual property right generic drug firm future event company guarantee forward file abbreviate new drug application anda seek look statement accurate company believe market generic form company key pharmaceutical reasonable expectation assumption product prior expiration applicable patent cover investor realize underlying assumption prove product event company successful defend inaccurate unknown risk uncertainty materialize actual patent claim challenge anda filing generic firm result vary materially company expectation introduce generic version product issue result projection investor caution place undue potential substantial market share revenue loss reliance forwardlooke statement company product information discussion litigation undertake update forwardlooke statement result filer abbreviate new drug application note new information future event development consolidate financial statement risk uncertainty include general industry condition competition economic condition interest rate currency legal proceeding exchange rate fluctuation technological advance new product company involve numerous product liability case patent attain competitor challenge inherent new united states concern allege adverse reaction product development include obtain regulatory approval drug medical device damage claim substantial challenge patent foreign health care reform company confident adequacy warning governmental law regulation trend health care cost instruction use accompany product containment increase scrutiny health care industry feasible predict ultimate outcome litigation government agency product efficacy safety concern result company believe liability result case product recall regulatory action substantially cover exist amount accrue company report year end company balance sheet selfinsurance program december include exhibit discussion additional thirdparty product liability insurance factor cause actual result differ expectation company involve number patent trademark company note factor permit private lawsuit investigation incidental security litigation reform act business ultimate legal financial liability company respect claim lawsuit proceeding refer estimate certainty company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial condition resolution management discussion analysis result operation financial condition consolidated balance sheet johnson johnson subsidiaries december december dollar million share share datum note asset current asset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note defer taxis income note prepay expense receivables total current asset marketable security noncurrent note property plant equipment net note intangible asset net note goodwill net note defer taxis income note asset note total asset liability shareholder equity current liability loan note payable note account payable accrue liability accrue rebate return promotions accrue salary wages commission accrue taxis income total current liability longterm debt note defer taxis income note employee relate obligation note liability total liability shareholder equity prefer stock par value authorize unissued share common stock par value share note authorize share issue share accumulate comprehensive income note retain earning common stock hold treasury cost note share share total shareholder equity total liability shareholders equity johnson johnson annual report note consolidated financial statementsconsolidate statement earnings johnson johnson subsidiarie dollar million share figure note sale customer cost product sell gross profit selling marketing administrative expense research expense purchase inprocess research development note restructure note interest income interest expense net portion capitalize note income expense net earning provision taxis income provision taxis income note net earning basic net earning share note dilute net earning share note cosnee noolteisd taot ceodns ofliidnaatend cfiinaalnc isalt satatteemmeenntst consolidated statement e quity johnson johnson subsidiaries accumulate treasury comprehensive retain comprehensive common stock stock dollar million note total income earning income issue balance january net earning cash dividend pay employee compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize loss security employee benefit plan loss derivative hedge reclassification adjustment total comprehensive income balance december net earning cash dividend pay employee compensation stock option plan conversion subordinate debenture repurchase common stock adoption fin comprehensive income net tax currency translation adjustment unrealize gain security employee benefit plan loss derivative hedge reclassification adjustment total comprehensive income balance december net earning cash dividend pay employee compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize loss security employee benefit plan gain derivative hedge reclassification adjustment total comprehensive income balance december johnson johnson annual report note consolidated financial statementsconsolidate statement cash flow johnson johnson subsidiaries dollar million note cash flow operating activity net earning adjustment reconcile net earning cash flow operating activity depreciation amortization property intangible stock base compensation purchase inprocess research development intangible asset writedown natrecor decreaseincrease defer tax provision account receivable allowance change asset liability net effect acquisition increase account receivable increasedecrease inventory decreaseincrease account payable accrue liability increase current noncurrent asset increase current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal asset acquisition net cash acquire note purchase investment sale investment primarily intangible net cash investing activity cash flow financing activity dividend shareholder repurchase common stock proceed shortterm debt retirement shortterm debt proceed longterm debt retirement longterm debt proceed exercise stock optionsexcess tax benefit net cash financing activity effect exchange rate change cash cash equivalent increasedecrease cash cash equivalent cash cash equivalent begin year note cash cash equivalent end year note supplemental cash flow datum cash pay year interest income taxis supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed conversion debt acquisition fair value asset acquire fair value liability assume net cash pay acquisition consolidated financial statement note consolidated financial statementsnote consolidated financial statement summary significant accounting policy eitf issue account nonrefundable advance principle consolidation payment good service receive use future consolidated financial statement include account research development activity issue effective johnson johnson subsidiaries company inter financial statement issue fiscal year begin company account transaction eliminate december adopt company fiscal quarter issue require nonrefundable advance description company business segment payment research development capitalize company approximately employee worldwide recognize expense relate good deliver service engage research development manufacture sale perform adoption eitf significant broad range product health care field company impact company result operation cash flow conduct business virtually country world financial position primary focus product relate human health wellbee company organize business segment recently issue accounting standard consumer pharmaceutical medical device diagnostic adopt december consumer segment manufacture market broad range december fasb issue sfas r business product baby care skin care oral care wound care combination noncontrolle interest consolidate women health care field nutritional overthe financial statement statement aim improve simplify counter pharmaceutical product product market converge internationally account business combination general public sell distributor directly report noncontrolle interest consolidate financial independent chain retail outlet world statement statement effective fiscal year begin pharmaceutical segment include product follow december sfas r significant therapeutic area antiinfective antipsychotic cardiovascular impact manner company account future contraceptive dermatology gastrointestinal hematology acquisition begin fiscal year significant change immunology neurology oncology pain management urology include capitalization inprocess research development virology product distribute directly retailer iprd expensing acquisition relate restructuring action wholesaler health care professional prescription use transaction relate cost recognition contingent purchase medical device diagnostic segment include broad range price consideration fair value acquisition date addition product principally professional field physician change account defer tax asset valuation allowance nurse therapist hospital diagnostic laboratory clinic acquire income tax uncertainty measurement period product include cordis circulatory disease management recognize earning adjustment product depuy orthopaedic joint reconstruction spinal care cost acquisition accounting treatment taxis applicable sport medicine product ethicon surgical care women acquisition occur prior subsequent health product ethicon endosurgerys minimally invasive surgical adoption sfas r company believe product lifescan blood glucose monitor insulin delivery adoption sfas r sfas product orthoclinical diagnostic professional diagnostic product material effect result operation cash flow financial vistakon disposable contact lense position march fasb issue sfas statement new accounting pronouncement disclosure derivative instrument hedge activity recently adopt accounting pronouncement amendment fasb statement enhance disclosure september financial accounting standard board company derivative hedging activity fasb issue statement financial accounting standard improve transparency financial reporting statement sfas fair value measurement statement define effective fiscal year begin november fair value establishe framework measure fair value adoption sfas impact company generally accept accounting principle expand disclosure result operation cash flow financial position fair value measurement statement effective eitf issue accounting collaborative arrangement fiscal quarter nonfinancial asset relate development commercialization intellectual liability recognize disclose fair value recur basis property issue effective financial statement issue effective date fiscal year begin fiscal year begin december issue november company adopt sfas address income statement classification payment fiscal quarter impact discuss note party collaborative arrangement adoption eitf expect significant impact company february fasb issue sfas fair value result operation cash flow financial position option financial asset financial liability permit eitf issue accounting defensive intangible asset entity measure certain financial asset financial liability issue apply acquire intangible asset situation fair value sfas effective fiscal year entity intend actively use asset intends hold company adopt fiscal quarter adoption asset prevent obtain access asset sfas material effect company intangible asset research result operation cash flow financial position development activity issue effective fiscal year begin december adoption eitf expect significant impact company result operation cash flow financial position johnson johnson annual reportthe returns reserve base historical return trend product c leha se ss h c w oe hmq ep nu pv n ua r l cce ho n sst eis de r ts ec u cr ait sie hs e w quit ih v lea ntu tsr itie month c n p p b r eoy rm ia vti er ok n ae dt l va p es r r oa tig p ir nae gmrc ase rn r u nto c g h eg mr ao es ns p trs soa al ue rcs et rli es cti rg ea dllo inw thn ec e ys e aa rnd incur continue promotional program include coupon investment volumebase sale incentive program redemption cost shortterm marketable security carry cost consumer coupon base historical redemption experience approximate fair value investment classified availableforsale product value volumebase incentive program base carry estimate fair value unrealize gain loss estimate sale volume incentive period record component accumulate comprehensive record product sell company earn service income longterm debt security company ability revenue copromotion certain product include sale intent hold maturity carry amortize cost customer promotional arrangement evaluate determine approximate fair value management determine appropriate amount defer appropriate classification investment debt equity addition company enter collaboration arrangement security time purchase reevaluate contain multiple revenue generating activity revenue determination balance sheet date company periodically arrangement recognize activity perform review investment equity security impairment deliver base relative fair value upfront fee receive adjust investment fair value decline market arrangement defer recognize revenue value deem temporary earn obligation period property plant equipment depreciation shipping handle property plant equipment state cost company shipping handling cost incur million utilize straightline method depreciation estimate million million respectively useful life asset include sell market administrative expense revenue receive shipping handle building building equipment year sale customer period present land leasehold improvement year machinery equipment year inventory company capitalize certain computer software inventory state low cost market determine development cost include machinery equipment firstin firstout method incur connection develop obtain computer software internal use capitalize software cost amortize intangible asset goodwill estimate useful life software generally range sfas require goodwill nonamortizable intangible year asset assess annually impairment company company review longlive asset assess recoverability complete annual impairment test fiscal fourth undiscounted cash flow necessary charge quarter impairment determine future impairment test impairment longlive asset record perform annually fiscal fourth quarter soon present value future cash flow carry trigger event occur value asset intangible asset finite useful life continue amortize useful life review impairment revenue recognition warrant economic condition note company recognize revenue product sale detail intangible asset good ship deliver title risk loss pass customer provision certain rebate sale incentive trade financial instrument promotion coupon product return discount customer company follow provision sfas accounting account reduction sale period relate derivative instrument hedging activity amend sale record sfas require derivative instrument record product discount grant base term balance sheet fair value change fair value arrangement direct indirect market participant derivative record period current earning market condition include price charge competitor comprehensive income depend derivative rebate large medicaid rebate provision designate hedge transaction type estimate base contractual term historical experience trend hedge transaction analysis project market condition market company use forward exchange contract manage serve company evaluate market condition product exposure variability cash flow primarily relate group product primarily analysis wholesaler foreign exchange rate change future intercompany product thirdparty sellthrough market research datum thirdparty purchase raw material denominate foreign internally generate information currency company use currency swap manage sale return generally estimate record base currency risk primarily relate borrowing type historical sale return information product exhibit unusual derivative designate cash flow hedge additionally sale return pattern date competition marketing company use forward exchange contract offset exposure matter specifically investigate analyze certain foreign currency denominate asset liability account sale return accrual sale return allowance forward exchange contract designate hedge represent reserve product return change fair value derivative expiration destruction field specific area product recall recognize currently earning offset current earning effect relate foreign currency asset liability note consolidated financial statement designation cash flow hedge entrance income taxis date derivative contract inception derivative company intend continue reinv undistribute expect highly effective change fair value international earning expand international operation derivative designate cash flow hedge highly tax expense record respect effective record accumulate comprehensive income undistribute portion intend repatriation december underlie transaction affect earning december cumulative reclassify earning account hedge undistributed international earning approximately billion transaction fair value derivative instrument ie forward billion respectively foreign exchange contract currency swap aggregation defer income taxis recognize tax consequence currency future cash flow discount present value temporary difference apply enact statutory tax rate prevail market interest rate subsequently convert applicable future year difference financial dollar current spot foreign exchange rate report tax basis exist asset liability ongoing basis company assess derivative continue highly effective offset change net earning share cash flow hedge item derivative long basic earning share compute divide net earning expect highly effective hedge accounting discontinue available common shareholder weight average number hedge ineffectiveness include current period earning common share outstanding period dilute earning insignificant share reflect potential dilution occur security company document relationship hedge item exercise convert common stock treasury stock derivative overall risk management strategy include method reason undertake hedge transaction enter derivative objective strategy minimize foreign use estimate currency exposure impact company financial performance preparation consolidate financial statement conformity protect company cash flow adverse movement accounting principle generally accept require foreign exchange rate ensure appropriateness financial management estimate assumption affect instrument manage enterprise risk associate amount report estimate accounting sale financial institution discount rebate allowance incentive product liability income taxis depreciation amortization employee benefit product liability contingency intangible asset liability valuation accrual product liability claim record undiscounted instance determine annual pension postemployment basis probable liability incur benefit cost company estimate rate return plan liability reasonably estimate base exist asset cost future health care benefit actual result information accrual adjust periodically additional differ estimate information available result cost availability factor effective november company cease annual closing date purchase thirdparty product liability insurance base company follow concept fiscal year end availability prior coverage receivables insurance recovery sunday nearest end month december normally relate product liability claim record undiscounted fiscal year consist week year basis probable recovery realize case fiscal year consist week research development reclassification research development expense expense incur certain prior period amount reclassify conform upfront milestone payment thirdpartie connection current year presentation research development collaboration expense incur point regulatory approval payment inventory thirdpartie subsequent regulatory approval capitalize end inventory comprise amortized remain useful life relate product inm tao nu gn ibts le c sa p ni eta l oiz fe ad c cfo ur uu lc ah te p da ay mm oe rn tit zs tir oe n ncluded rd aol wlar teil rli io ls supply good process advertising finish good c ano ds r es cc luia dt ee dd iw n tt hh e sd ev le linrt gis n mg rkre e te inx gp e ns de ad mn nh ie st ry ae ta ivr e incur expense advertising expense worldwide comprise television radio print medium internet advertising billion billion billion johnson johnson annual report property plant equipment borrowing end property plant equipment cost component longterm debt follow accumulate depreciation effective effective ld ao nlla drs n il aio nn improvement ol la zr es rin cil olio un ps n rate rate building build equipment convertible subordinate machinery equipment e b e n dtu er es n tuu e u e construction progress debenture note accumulate depreciation debenture note debenture company capitalize interest expense cost note construction facility equipment interest expense capitalize note million million g nb op te u e gbp million respectively b euro e ree sp tr e inc ti n e x p e n ne c l u n wg sh e br ilt li iz oa nt n f bc ia llp ioit na l aiz ne dd b e u dr eo b e n u r e ue billion respectively debenture retirement disposal property plant debenture equipment cost relate amount accumulate include industrial revenue depreciation amortization eliminate asset bond accumulate depreciation account respectively difference net asset value proceed record current portion earning rental expense lease commitment w trae nig sh late tid na v rae tr ea g ae def efe cc et miv e r ra te rental space vehicle manufacture equipment office translation rate december datum processing equipment operating lease excess fair value carry value debt billion approximately million million billion million company access substantial source fund approximate minimum rental payment require numerous bank worldwide september company operating lease initial remain noncancelable lease secure new day year credit facility total credit term excess year december available company approximate billion billion expire september billion expire dollar million september interest charge borrowing credit total line agreement base bid provide bank prime rate london interbank offer rate libor plus applicable margin commitment fee agreement material commitment capital lease significant company file shelf registration security exchange commission effective march employee relate obligation enable company issue unlimited aggregate principal end employee relate obligation debt security warrant purchase debt security company issue bond june total billion dollar million general corporate purpose pension benefit july alza corporation subsidiary postretirement benefit company complete private offering zero coupon postemployment benefit convertible subordinated debenture issue price defer compensation principal maturity term total employee obligation debenture holder entitle convert current benefit payable debenture approximately million share johnson employee relate obligation longterm johnson stock price share approximately million share issue december prepay employee relate obligation million million voluntary conversion note holder option holder respectively include asset debenture repurchase company july consolidated balance sheet purchase price equal issue price plus accrete original issue discount purchase date company option redeem debenture july issue price plus accrete original issue discount note consolidated financial statement company continue access weight average amortization period patent liquidity commercial paper market shortterm borrowing trademark intangible asset year year current portion longterm debt amount approximately respectively amortization expense amortizable asset billion end billion raise fiscal year end december december commercial paper program remainder represent december million million million principally local borrowing international subsidiary tax respectively certain patent intangible asset aggregate maturity longterm obligation commence write fair value fiscal year result charge include amortization expense estimate amortization expense succeed year dollar million approximate million tax year substantially amortization expense include cost product sell intangible asset goodwill income taxis st sth ee ts e nd gf w la l wnd e r e gross net unt f n angible h cde uo p l rla rr ero n v ti ls ymi plln io n yf ar b la ex es income con f l pd er r ao asl tl ea sr e e n ti scn acm aur ri nk kl mli ds son u ts l rn n ao ot den n ed ro kor r st tri z zi za aab b gl lie eo ro n g nr eo tss du un e fs se e r r n rt tea aa dx xti e eos snal taxis accumulate amortization international taxis patent trademark net intangible gross accumulate amortization intangible net comparison income tax expense statutory rate subtotal intangible asset gross company effective tax rate accumulate amortization follow gu ob ot wta ill l nta gn rg oi sb sle assets net ud slla r million accumulate amortization international goodwill net earning taxis income total intangible asset goodwill gross tax rate accumulate amortization statutory rate total intangible asset goodwill net puerto rico ireland operation goodwill december december research orphan drug tax allocate segment business follow credit state local med dev international subsidiary dollar million consumer pharm diag total exclude ireland goodwill december manufacture deduction process research acquisition development iprd translationother tax international income w ill december el fl f eo cth tie ver tax rate acquisition company subsidiary manufacture ireland translationother incentive tax rate addition company subsidiary goodwill december operate puerto rico tax incentive grant increase tax rate mainly attribute increase taxable income high tax jurisdiction relative taxable income low jurisdiction decrease tax rate mainly attribute business restructure certain international subsidiary result onetime benefit million reduce effective tax rate johnson johnson annual reporttemporary difference carry forwards international currency translation follow translation subsidiary operate nonus dollar currency company determine local currency international subsidiary functional currency defer tax defer tax highly inflationary economy define dollar million asset liability asset liability compound cumulative rate inflation employee relate past year substantial portion obligation cash flow local currency stock base compensation consolidate international subsidiary balance sheet currency depreciation effect record component accumulate nondeductible intangible comprehensive income equity account include result international rd translate balance sheet asset liability current exchange capitalize tax rate locate highly inflationary economy reserve liabilitie translation balance sheet account highly inflationary income report tax economy reflect operating result purpose analysis change miscellaneous international foreign currency translation adjustment include note capitalize intangible net currency transaction translation gain loss miscellaneous include income expense loss million total deferred income million million respectively tax common stock stock option plan difference net defer tax income stock compensation agreement balance sheet net defer tax include taxis income balance sheet defer tax miscellaneous stock option include current year tax receivables december company stockbase company adopt fin accounting uncertainty compensation plan share outstanding contract income taxis effective january company company stock option plan long billion gross unrecognized tax benefit december term incentive plan nonemployee director plan company classifie liability unrecognize tax benefit centocor innovasive device alza inverness scios stock relate interest penalty longterm liabilitie interest option plan option restrict share expense penalty relate unrecognized tax benefit grant plan longterm classify income tax expense fiscal year end incentive plan december company recognize million interest compensation cost record sfas r expense aftertax impact million year end charge income plan million december company recognize million interest million million total expense million interest income aftertax impact income tax benefit recognize income statement share million expense total accrue interest base compensation cost million million million million respectively million sharebased compensation cost follow table summarize activity relate capitalize inventory insignificant period unrecognize tax benefit stock option expire year date grant vest service period range month year option dollar million grant average high low price begin year company common stock new york stock exchange increase relate current year tax position date grant longterm incentive plan increase relate prior period tax position company issue million share common stock decrease relate prior period tax position share available future grant longterm settlement incentive plan million end lapse statute limitation end year unrecognize tax benefit approximately billion december recognize affect company annual effective tax rate company conduct business file tax return numerous country currently tax audits progress number tax authority internal revenue service irs complete audit tax year major jurisdiction company conduct business year remain open generally year jurisdiction remain open far company expect total unrecognized tax benefit significantly change month company expect significant payment month able provide reasonably reliable estimate time future tax payment relate uncertain tax position note consolidated financial statement company settle employee stock option exercise follow table summarize stock option outstanding treasury share treasury share replenish exercisable december year number share settle employee stock option exercise share thousand outstanding exercisable fair value option award estimate date average average grant blackschole option valuation model use e px rie cr ec rs ae nge option aver lag ife e exe prc ri ce e option exe prc ri ce e assumption note follow table expect volatility represent blend rate year daily historical average volatility rate week average imply volatility rate base atthe money trade johnson johnson option life year historical datum determine expect life option riskfree rate base treasury yield curve effect time grant average fair value option grant respectively fair value estimate base weighted average assumption average contractual life remain year riskfree rate stock option exercisable december december expect volatility average price average life expect life yrs yrs yrs year average price dividend yield average life year respectively summary option activity plan december restrict share unit december december change year end date present company grant restrict share unit vest period year company settle employee stock issuance treasury share treasury share replenish weight ag ig nr tre ig na st ie c year number share employee stock issuance outstanding average value summary share activity plan december share thousand share exercise price dollar million share january op ti n grant share thousands outst san hd arin eg option exercise share january option share grant canceledforfeite share issue share share canceledforfeite december share december share grant option grant share issue option exercise share canceledforfeite option share december canceledforfeite share grant share share issue december share canceledforfeite share december option grant average fair value restrict share unit grant option exercise respectively option fair market value date grant fair value canceledforfeite restricted share unit discount dividend share pay restricted share unit vest period fair december value restrict share unit settle million million million respectively total intrinsic value option exercise million million million respectively total unrecognized compensation cost million december million december million december weight average period cost recognize year year year respectively johnson johnson annual report segment business geographic area sale customer dollar million consumer united states international total pharmaceutical united states international total medical device diagnostic united states international total worldwide total operating profit identifiable asset dollar million consumer pharmaceutical medical device diagnostic total income expense allocate segment general corporate worldwide total addition property depreciation plant equipment amortization dollar million consumer pharmaceutical medical device diagnostic segment total general corporate worldwide total sale customer longlive asset dollar millions united states europe western hemisphere exclude asiapacific africa segment total general corporate non longlived asset worldwide total note description segment company operate export sale significant company customer represent total revenue amount allocate segment include interest income expense minority interest general corporate income expense general corporate include cash marketable security include million million inprocess research development iprd consumer medical device diagnostic segment respectively include million fourth quarter net litigation gain comprise million expense consumer segment gain million medical device diagnostic segment medical device diagnostic segment include million gain divestiture professional wound care business ethicon inc include million restructure expense comprise million million million consumer pharmaceutical medical device diagnostic segment respectively medical device diagnostic segment include million iprd pharmaceutical segment include million writedown natrecor intangible asset include million million iprd consumer medical device diagnostic segment respectively medical device diagnostic segment include guidant acquisition agreement termination fee associate expense million longlive asset include property plant equipment net respectively intangible asset goodwill net respectively note consolidated financial statement tax effect unrealize gainslosses equity accumulate comprehensive income security expense million million million component comprehensive incomeloss consist respectively tax effect relate follow employee benefit plan million million million respectively tax effect u nrealize gain accumut lao teta dl gainslosses derivative hedge loss foreign gain loss million gain million loss million currency loss employee derivative comprehensive note additional information relate derivative jd ao nl ula ar r yin ill io n tra nsl ti n securiti e benefit p la n hedg e income l hedging change currency translation adjustment currently adjust net change income taxis relate permanent investment hedge international subsidiary transaction net reclasse net pension benefit plan nee ta rn n g change inh ce lu c dio nm g p da en fiy n es dp bn es er fs v da eri fo inu es r e ct oir ne tm ribe un tt oa nn np de n te ri mon p al ta ion n december indemnity plan cover employee worldwide n e cc hh aa nn gg ee company provide postretirement benefit primarily health care hedge retired employee dependent transaction international employee cover government ne ret lm aso su en dt net sponsor program cost company significant earning retirement plan benefit primarily base employee net change compensation year retirement december number year service international subsidiary change plan fund deposit trustee annuitie net change purchase group contract reserve provide h tre ad ng sain cg tion company fund retiree health care benefit net advance right modify plan future reclasse net company use date consolidate financial nee ta rn n g change reta st pe em ce tivn ets ly ae sc te hm e b er u r e e n n dd td e e foce r alb l uer n ernational december retirement benefit plan total comprehensive income include reclassification september statement financial accounting standard adjustment gain million realize sale equity sfas employer account define benefit pension security associate tax expense million postretirement plan issue amend total comprehensive income include reclassification disclosure requirement pension postretirement adjustment gain million realize sale equity benefit statement amendment fasb statement security associate tax expense million r incremental effect apply fasb total comprehensive income include billion reduction shareholder equity net reclassification adjustment gain million realize sale defer taxis equity security associate tax expense million johnson johnson annual reportnet periodic benefit cost company define benefit retirement plan benefit plan include follow component retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost amortization net transition asset recognize actuarial loss curtailment settlement net periodic benefit cost net periodic benefit cost attributable retirement plan million million million respectively amount expect recognize net periodic benefit cost life expectancy amortization gain loss come year company define benefit retirement plan benefit plan determine corridor postretirement plan great market value asset project benefit obligation total unamortized gain loss excess dollar million corridor amortize average remain future service amortization net transition obligation prior service costsbenefit pension plan amortization net actuarial loss amortize remain future service plan participant amortization prior service cost time plan amendment prior service costbenefit benefit plan amortize average remain service unrecognized gain loss pension plan eligibility age plan participant time plan amortize average remain future service plan amendment plan active employee amortize average weightedaverage assumption follow table represent rate develop actuarial present value project benefit obligation year list net periodic benefit cost follow year retirement plan benefit plan dollar million benefit plan discount rate expect longterm rate return plan asset rate increase compensation level international benefit plan discount rate expect longterm rate return plan asset rate increase compensation level company discount rate determine consider current follow table display assume health care cost trend yield curve represent high quality longterm fix income rate individual instrument result discount rate consistent duration plan liabilitie health care plan expect longterm rate return plan asset assumption health care cost trend rate assume determined building block approach consider historical year average real return asset class certain country rate cost trend rate assume historical return meaningful consideration give decline ultimate trend local market expectation longterm return year rate reach ultimate trend rate onepercentagepoint change assume health care cost trend rate follow effect onepercentage onepercentage dollar million point increase point decrease health care plan total interest service cost postretirement benefit obligation note consolidated financial statement follow table set forth information relate benefit obligation fair value plan asset yearend company define benefit retirement plan postretirement plan retirement plan benefit plan dollar million change benefit obligation project benefit obligation begin year service cost interest cost plan participant contribution amendment actuarial gain loss divestiture acquisition curtailment settlement benefit pay plan effect exchange rate project benefit obligation end year change plan asset plan asset fair value begin year actual return loss plan asset company contribution plan participant contribution settlement divestiture acquisition benefit pay plan asset effect exchange rate plan asset fair value end year fund status end year amount recognize company balance sheet consist follow noncurrent asset current liability noncurrent liability total recognize consolidated balance sheet end year amount recognize accumulated comprehensive incom e consist follow net actuarial gain loss prior service cost credit unrecognized net transition asset total tax effect accumulate benefit obligation end year change plan asset benefit obligation recognize ot comprehensive income net periodic benefit cost net actuarial loss gain amortization net actuarial loss prior service cost amortization prior service cost effect exchange rate total recognize comprehensive income tax total recognize net periodic benefit cost comprehensive income company fund certain plan fund require billion project benefit obligation billion underfunded status billion accumulate benefit obligation fiscal year relate unfunded pension plan plan accumulate benefit obligation excess plan asset consist follow retirement plan dollar million accumulate benefit obligation project benefit obligation plan asset fair value johnson johnson annual reportstrategic asset allocation determine country base nonmature plan longterm strategic asset allocation nature liability consider demographic consistent type plan emphasis place composition plan participant average age year service diversify equity broad basis combine currency active versus retiree status company plan match fix income asset consider follow table display project future benefit payment companys retirement benefit plan dollar million project future benefit payment retirement plan benefit plan gross medicare rebate benefit plan net company contribute million million international plan fund accordance local international pension plan respectively addition regulation additional discretionary contribution company fund million plan deem appropriate meet longterm obligation plan month certain plan fund common practice funding congress pass pension protection act provide economic benefit consequently company act amend employee retirement income security act pension plan fund erisa plan year beginning establish new minimum funding standard employer define benefit plan company plan continue fund define benefit plan comply act follow table display project future minimum contribution company international unfunded retirement plan amount include discretionary contribution company elect future dollar million project future contribution unfunde retirement plan unfunde international retirement plan company retirement plan asset allocation end target allocation follow percent target plan asset allocation retirement plan equity security debt security total plan asset international retirement plan equity security debt security real estate total plan asset company benefit plan unfunded fair value johnson johnson common stock directly life insurance contract asset million million hold plan asset million total plan asset december december respectively december million total plan asset december note consolidated financial statement cash cash equivalent marketable security december december amortize unrealized estimate amortize unrealized estimate dollar million cost gainslosse fair value cost gainslosse fair value current investment cash government security obligation corporate debt security money market fund time deposit total cash cash equivalent current marketable security noncurrent investment marketable security december current marketable security consist heshe eligible total company match contribution plan million million million government security million million million obligation corporate debt security time deposit respectively december current marketable security consist merger acquisition divestiture million million government security certain business acquire million cash obligation corporate debt respectively million liability assume acquisition account purchase method accordingly result concentration credit risk operation include financial statement company invest excess cash deposit major respective date acquisition bank world highquality money market acquisition include amic ab privately hold instrument company policy make investment swedish developer vitro diagnostic technology use point commercial institution equivalent ofcare nearpatient setting beijing dabao cosmetics co ltd credit rating company sell personal care brand china surgrx inc privately hold developer advance bipolar tissue seal financial instrument system enseal family device healthmedia inc derivative instrument record balance sheet fair privately hold company create webbase behavior change value note additional detail intervention lge performance systems inc privately hold december balance defer net gain company know human performance institute develop derivative include accumulate comprehensive income sciencebase training program improve employee engagement million aftertax additional information note productivity omrix biopharmaceutical inc fully company expect substantially integrate biopharmaceutical company develop market reclassify earning month result biosurgical immunotherapy product transaction expect occur period excess purchase price estimate fair value maximum length time company hedge tangible asset acquire amount million transaction exposure month ultimately realize assign identifiable intangible asset residual record earning differ foreign exchange rate change realize gain goodwill approximately million identify loss ultimately determine actual exchange rate value iprd associate acquisition omrix maturity derivative derivative gainslosse initially report biopharmaceuticals inc amic ab surgrx inc healthmedia component comprehensive income reclassify inc earning period forecast transaction affect iprd charge relate acquisition omrix earning biopharmaceutical inc million associate fiscal year end december december standalone combination biosurgical technology december net impact hedge achieve hemostasis value iprd calculate ineffectiveness transaction qualify hedge accounting cash flow projection discount risk inherent project discontinuance hedge company financial statement probability success factor range insignificant reflect inherent clinical regulatory risk discount rate apply refer note disclosure movement accumulate end fiscal year comprehensive income outstanding share common stock omrix biopharmaceutical inc tender stockholder exclude share saving plan tender subject guarantee delivery procedure company voluntary k saving plan design outstanding share common stock tender enhance exist retirement program cover eligible december company complete acquisition omrix employee company match percentage biopharmaceutical inc employee contribution consistent provision plan iprd charge relate acquisition amic ab million associate pointofcare device cast chip technology value iprd calculate cash flow projection discount risk inherent project discount rate apply johnson johnson annual report mh ile lio np r ndd isc h aa sr sg oe c r iae tl ea dte wd h vh ee sa ec lq cu uis ttit inio gn ao nf ds su erg ar linx g sn uc r g w ica l unaudite pro fo yrm e aa r r ee ns du elt ds devices value iprd calculate cash flow december projection discount risk inherent project share million share datum probability success factor range net sale reflect inherent clinical regulatory risk discount rate apply net earning dilute net earning share iprd charge relate acquisition healthmedia inc million associate primarily process iprd charge relate acquisition consumer enhancement software technology value iprd healthcare business pfizer inc million pretax calculate cash flow projection discount risk inherent basis million aftertax basis primarily project probability success factor associate right obtain switch zyrtec reflect inherent risk discount rate apply prescription overthecounter status switch approve certain business acquire million cash fda effective november value iprd million liability assume acquisition calculate cash flow projection discount risk inherent account purchase method accordingly result project probability success factor operation include financial statement reflect inherent regulatory risk acquisition date respective date acquisition discount rate apply acquisition include conor medsystems inc company complete analysis integration plan cardiovascular device company new drug delivery technology pursuant company incur cost primarily relate robert reid inc japanese orthopedic product distributor elimination certain duplicate sell general administrative mayas mom inc social medium company function company area global excess purchase price estimate fair value business service corporate staff gotomarket support tangible asset acquire amount million excess manufacturing capacity assign identifiable intangible asset residual record addition acquisition consumer healthcare goodwill approximately million identify business pfizer inc acquisition include animas value iprd associate acquisition conor corporation lead maker insulin infusion pump relate medsystem inc product hand innovation llc privately hold manufacturer iprd charge relate acquisition conor fracture fixation product upper extremity future medical medsystem inc million associate research system sa privately hold company primarily develop related discovery application stent technology manufacture market arthroscopic fluid management system value iprd calculate cash flow projection vascular control systems inc privately hold company focus discount risk inherent project discount rate develop medical device treat fibroid control bleeding apply obstetric gynecologic application groupe vendme sa certain business acquire billion cash privately hold french marketer adult baby skin care product billion liability assume acquisition colbar lifescience ltd privately hold company specialize account purchase method accordingly result reconstructive medicine tissue engineering ensure medical operation include financial statement inc privately hold company develop device post respective date acquisition note catheterization closure femoral artery december company complete acquisition exclude acquisition consumer healthcare business consumer healthcare business pfizer inc purchase pfizer inc excess purchase price estimate fair value price billion cash operating result consumer tangible asset acquire amount million healthcare business pfizer inc report company assign identifiable intangible asset residual financial statement begin result subsequent record goodwill approximately million identify acquisition date significant value iprd primarily associate acquisition order obtain regulatory approval transaction hand innovation llc future medical system sa vascular company agree divest certain overlapping business control systems inc colbar lifescience ltd ensure medical company complete divestiture zantac product inc december divestiture kaopectate iprd charge relate acquisition hand innovation unisom cortizone balmex act product llc million associate fracture repair january technologies value iprd calculate cash flow follow table provide pro forma result operation projection discount risk inherent project fiscal year end december consumer healthcare probability success factor range business pfizer inc acquire beginning reflect inherent clinical regulatory risk discount rate period present pro forma result include effect apply divestiture certain purchase accounting adjustment iprd charge relate acquisition future medical estimate change depreciation amortization expense system sa million associate nextra acquire tangible intangible asset pro forma duo pump product technology value iprd result include anticipate cost saving effect calculate cash flow projection discount risk inherent planned integration consumer healthcare business project probability success factor pfizer inc accordingly amount necessarily indicative technology reflect inherent clinical regulatory risk result acquisition occur date indicate discount rate apply occur future iprd charge relate acquisition vascular control systems inc million associate flostat system technology value iprd calculate cash flow projection discount risk inherent project note consolidated financial statement probability success factor reflect inherent allege overpayment risperdal seek clinical regulatory risk discount rate apply certification class action case bring attorney iprd charge relate acquisition colbar general west virginia base claim allege consumer lifescience ltd million associate fraud duragesic risperdal janssen evolence family product biodegradable dermal find liable motion damage likely assess filler value iprd calculate cash flow million janssen intend seek appeal projection discount risk inherent project numerous claim lawsuit united states relate probability success factor range drug propulsid withdraw general sale company reflect inherent clinical regulatory risk discount rate janssen subsidiary resolve currently apply enrol settlement program aggregate cap iprd charge relate acquisition ensure medical million litigation concern propulsid pende inc million associate femoral artery closure canada class action person allege adverse reaction device value iprd calculate cash flow drug certify projection discount risk inherent project probability success factor reflect inherent affirmative stent patent litigation clinical regulatory risk discount rate apply patent infringement action try delaware federal district court exception consumer healthcare business pfizer late cordis corporation cordis subsidiary johnson inc supplemental pro forma information johnson obtain verdict infringement patent validity sfas business combination sfas damage awards boston scientific corporation boston goodwill intangible asset provide impact scientific medtronic ave inc medtronic base number aforementione acquisition material effect cordis vascular stent patent december jury company result operation cash flow financial position damage action boston scientific return verdict exception divestiture professional wound million jury medtronic action return verdict care business ethicon inc result gain million court appeal federal circuit uphold million tax record income expense liability case september district court net divestiture enter judgment include interest amount million material effect company result operation cash flow million boston scientific medtronic financial position respectively medtronic pay million october represent judgment net amount exchange settlement legal proceeding number litigation company net product liability settlement million record credit company subsidiary involve numerous product income expense net consolidated statement liability case unite states concern allege earning million judgment boston scientific adverse reaction drug medical device damage reflect financial statement boston scientific claim substantial company confident appeal judgment amount receive adequacy warning instruction use accompany cordis arbitration medtronic seek product feasible predict ultimate outcome royalty sale stent product introduce medtronic litigation company believe product liability subsequent december pursuant crosslicense result case substantially cover exist agreement cordis medtronic hearing amount accrue company balance sheet arbitration place march available thirdparty product liability insurance january cordis file patent infringement action multiple product johnson johnson subsidiaries subject boston scientific delaware federal district court accuse numerous product liability claim lawsuit include ortho express taxus liberte stent infringe palmaz evra risperdal duragesic cypher stent patent expire november liberte stent charit artificial disc approximately claimant accuse infringe cordis gray patent expire pende lawsuit claim injury allegedly june jury find express taxus liberte ortho evra respect risperdal stent infringe palmaz patent liberte stent respect charit respect cypher infringe gray patent boston scientific appeal respect duragesic claimant seek substantial court appeal federal circuit compensatory available punitive damage cordis file lawsuit new jersey federal district respect risperdal attorney general court guidant corporation guidant abbott laboratories state office general counsel commonwealth inc abbott boston scientific medtronic allege xience pennsylvania file action seek reimbursement medicaid v abbott promus boston scientific endeavor public fund risperdal prescription write medtronic drug eluting stent infringe patent own label use compensation treat citizen allege adverse license cordis october cordis file suit boston reaction risperdal civil fine penalty punitive damage scientific delaware federal court accuse taxus liberte relief attorney general texas join qui tam stent infringe gray patent action state seek similar relief certain action seek injunctive relief relate promotion risperdal patent litigation johnson johnson attorney general state indicate subsidiary potential interest pursue similar litigation company product johnson johnson subsidiaries janssen subsidiary orthomcneiljanssen pharmaceutical subject patent lawsuit outcome inc omjpi obtain tolling agreement stay potentially adversely affect ability subsidiary run statute limitation inquire issue addition case file union health plan seek damage johnson johnson annual reportsell product require payment past damage appeal dutch supreme court october boston future royalties scientific prevail nullity action challenge validity july jury federal district court delaware find kastenhofer patent file cordis germany cordis appeal cordis cypher stent infringe boston scientific de substantive hearing schedule french patent cordis cypher bx velocity italian action stent infringe boston scientifics jang patent jury trial boston scientific case base kastenhofer find patent valid boston scientific seek patent federal district court california conclude substantial damage injunction action cordis october jury find patent invalid jury appeal january court appeal federal find cordis counterclaim sale boston circuit hold de patent invalid expect boston scientific balloon catheter stent delivery system infringe scientific reconsideration appeal jang cordis fontirroche patent court deny boston scientifics patent case pende judgment uphold post trial motion consider appropriate remedy remand trial issue damage injunctive relief future infringement germany boston scientific action base centocor inc cobi file lawsuit de patent pende cordis cypher stent cordis genentech inc genentech district court central successful action trial level boston scientific district california seek invalidate cabilly ii patent prior appeal boston scientific bring action belgium filing suit centocor sublicense patent celltech netherlands germany france italy kastenhofer license genentech remicade patent purport cover twolayer catheter pay royalty celltech centocor terminate sublicense deliver cypher stent enjoin manufacture stop pay royalty genentech file counterclaim sale allegedly infringe catheter country allege remicade infringe cabilly ii patent recover damage decision low court netherlands manufacture remicade ustekinumab golimumab reopro boston scientifics favor reverse appeal april infringe patent relate purification antibodie boston scientific file recombinant dna technique follow chart summarize patent lawsuit concern product johnson johnson subsidiary proceed trial plaintiff trial date jj product company patent patent holder court date file twolayer catheter cordis kastenhofer boston scientific multiple european corp contact lense vision care nicolson ciba vision md fl cypher stent cordis wall wall ed tx cypher stent cordis bonutti marctec sd il cypher stent cordis saffran saffran ed tx stentcatheter delivery system cordisethicon schock cardio access llc ed tx listerine tooth whiten mcneilppc sagel procter gamble wd wi strip blood glucose meter strip lifescan wilsey roche diagnostic de remicade ustekinumab centocor cabilly ii genentech cd golimumab reopro trial date schedule noninfringement invalidity unenforceability patent l ai pt pig la ict aio tn io ng sa ns dt f si ler abbreviate new drug event subsidiary company involve successful follow chart indicate lawsuit pende generic firm action statutory month stay expire ruling file abbreviate new drug application anda seek district court obtain firm involve market generic form product sell subsidiary ability fda approval introduce generic version company prior expiration applicable patent cover product issue result substantial market share product anda typically include allegation revenue loss product company subsidiary note consolidated financial statement note follow chart month stay expire expire respect anda challenge product brand patentnda generic trial date month product holder challenger court date file stay expiration concerta mcneilppc andrx de mg control alza release tablet levaquin mg orthomcneil lupin nj tablet ortho tricyclen lo orthomcneil barr nj mg mg mg watson nj mg mg mg razadyne janssen teva de mylan de dr reddys de purepac de barr de alphapharm de razadyne er janssen barr nj sandoz nj kv pharma nj ultram er mg orthomcneil par de tablet ultram er mg tablet orthomcneil impax de janssen trial date schedule action barr pharmaceuticals inc barr stay pende appeal delaware decision litigation ortho tricyclen lo january companys barr kv sandoz razadyne er formulation patent subsidiary ortho womens health urology division ortho proceeding barr receive fda approval product mcneiljanssen pharmaceuticals inc barr agree non launch risk bind term sheet settle litigation settlement action lupin pharmaceuticals inc lupin discussion underway trial court postpone anda concern levaquin lupin contend january trial set new trial date united states patent trademark office improperly grant october company subsidiary orthomcneil patent term extension patent orthomcneil ortho janssen pharmaceuticals inc omjpi file suit federal district mcneiljanssen pharmaceuticals inc omjpi license daiichi court new jersey watson laboratories inc watson pharmaceuticals inc daiichi lupin allege active response watson anda ortho tricyclen lo ingredient levaquin subject prior marketing action barr alphapharm respect eligible patent term extension lupin anda challenge razadyne patent janssen license concede validity product violate patent synaptech inc synaptech fourday nonjury trial hold market prior expiration original patent term federal district court delaware august ultram er action orthomcneil omjpi file court hold patent invalid lawsuit different dosage par pharmaceutical enable janssen synaptech appeal decision inc par pharmaceuticals companies inc par june court decision generic company receive final october tramadol er formulation patent own approval product launch risk pende purdue pharma product lp purdue napp pharmaceutical appeal additional generic approval launch occur group ltd napp omjpi file lawsuit different time dosage impax laboratories inc impax tramadol er action mcneilppc inc andrx corporation formulation patent own purdue napp august andrx respect anda challenge concerta november purdue napp biovail laboratory international patent fiveday nonjury trial hold federal district court srl biovailthe nda holder join coplaintiff lawsuit delaware december court issue rule par impax action razadyne er case lawsuit file barr average wholesale price awp litigation razadyne use patent janssen licenses synaptech johnson johnson pharmaceutical subsidiary june razadyne er formulation patent numerous pharmaceutical company march lawsuit different dosage file defendant series lawsuit state federal court involve kv pharmaceutical company kv razadyne er allegation pricing market certain pharmaceutical formulation patent december june suit file product amount fraudulent actionable conduct sandoz razadyne use patent janssen thing company allegedly report license synaptech razadyne er inflated average wholesale price awp drug issue formulation patent june september case federal action state action remove discuss delaware decision invalidate razadyne use federal court consolidated pretrial purpose patent result entry judgment barr patent multidistrict litigation mdl federal district court boston case sandoz patent massachusetts plaintiff case include class private person entity pay portion johnson johnson annual reportpurchase drug issue base awp state government court appeal rule plaintiff appeal denial class entity medicaid payment drug issue base certification untimely plaintiff engage awp discovery individual plaintiff claim mdl court identify class massachusettsonly private march depuy orthopaedics inc depuy johnson insurer provide medigap insurance coverage private payer johnson subsidiary receive subpoena attorney physicianadministere drug payment base office district new jersey seek record concern awp class class national class individual contractual relationship depuy surgeon surgeon copayment physicianadministere drug cover intraining involve hip knee replacement reconstructive medicare class trial massachusettsonly class surgery investigation resolve depuy action conclude mdl court december lead supplier hip knee implant late september june mdl court issue posttrial ruling dismiss agreement attorney office district new johnson johnson defendant case claim jersey settlement include month defer prosecution class subsequently class rule agreement dpa acceptance company monitor subject pende appeal awp case bring assure compliance dpa respect attorney general proceed trial company payment settlement monie entry year manufacturer case include johnson johnson subsidiaries corporate integrity agreement depuy pay million expect set trial settlement november attorney general commonwealth massachusetts issue civil investigative demand depuy seek information financial relationship july centocor cobi johnson johnson subsidiary number massachusettsbase orthopedic surgeon receive request voluntarily provide document provider depuy relationship publicly information criminal division attorney office disclose depuy pursuant dpa february depuy district new jersey connection investigation receive write request information senate centocor marketing practice subsequent request document special committee age followup early inquiry receive attorney office concern number aspect dpa company centocor respond request july scios inc scios johnson johnson subsidiary document information receive subpoena attorney office district december orthomcneil omjpi receive massachusetts seek document relate sale subpoena attorney office boston massachusetts marketing natrecor scio respond subpoena seek document relate marketing include allege early august scio advise investigation label marketing drug topamax topiramate additional handle attorney office northern district subpoenas document receive current california san francisco additional request document employee testify grand jury discussion receive respond current scio underway effort resolve matter agreement employee testify grand jury san francisco reach term uncertain september johnson johnson receive subpoena january janssen omjpi receive subpoena attorney office district massachusett seek office inspector general office document relate sale marketing drug omni personnel management seek document concern sales care inc manager pharmaceutical benefit longterm care marketing payment physician connection facilities johnson johnson subsidiary involve respond sale marketing clinical trial risperdal subpoena employee company pharmaceutical risperidone document subsequent subsidiary subpoenaed testify grand jury request additional subpoena seek connection investigation information marketing adverse reaction november amgen file suit hoffmannlaroche risperdal receive attorney office inc roche district court district eastern district pennsylvania november subpoenas massachusetts seek declaration roche product cera seek testimony witness grand jury roche indicate seek introduce united receive janssen cooperate respond state infringe number amgen patent concern epo subpoena amgen licenses epo sale united states ortho biotech september ortho biotech inc cobi receive cobi nondialysis indication trial action conclude subpoena office inspector general denver october verdict amgen favor find patent colorado field office seek document direct sale valid infringe judge issue preliminary injunction block marketing procrit epoetin alfa present cera launch say consider modify dealing oncology inc healthcare service injunction grant roche compulsory license allow network oncologist ortho biotech cobi respond launch pay percent royalty subsequent subpoena decision district judge indicate grant roche september plaintiffs employment discrimination compulsory license litigation initiate company federal district february johnson johnson receive subpoena court new jersey move certify class african american securities exchange commission sec request hispanic salaried employee company affiliate document relate participation johnson employ time november johnson subsidiaries united nations iraq oil food present plaintiff seek monetary damage period program subsidiary cooperate sec present include punitive damage equitable relief department justice doj produce responsive document court deny plaintiff class certification motion december motion reconsideration april plaintiff seek appeal decision april note consolidated financial statement september janssen omjpi receive subpoena march company receive letter request attorney general state california seek attorney general state michigan request seek document sale marketing sideeffect document information relate nominal price transaction risperdal interaction state official company respond request cooperate state formulary medicaidreimburse drug janssen inquiry omjpi respond subpoena june johnson johnson receive subpoena february johnson johnson voluntarily disclose united states attorney office district massachusetts doj sec subsidiary outside united states relate marketing biliary stent company cordis believe improper payment connection subsidiary cordis cooperate respond subpoena sale medical device smallmarket country september multilan ag indirect subsidiary payment fall jurisdiction foreign corrupt scheringplough corporation commence arbitration practice act fcpa course continue dialogue janssen pharmaceutica nv allege wrongful termination agency issue potentially rise level fcpa agreement relate payment connection termination violation additional market bring attention certain marketing right multilan seek declaratory relief specific agency company company provide performance damage multilan allege damage exceed continue provide additional information doj sec million party process select arbitral cooperate agency review matter law tribunal enforcement agency number country recent year company receive numerous request pursue investigation matter voluntarily disclose variety united states congressional committee produce company doj sec discussion underway effort information relevant ongoing congressional inquiry resolve matter iraq oil food matter reference company policy cooperate inquiry produce agreement reach term request information uncertain respect matter company march company receive separate subpoena subsidiary vigorously contest allegation assert attorney office philadelphia attorney office pursue defense maximize boston attorneys office san francisco prospect success company subsidiary involve subpoena relate investigation office reference matter continually evaluate strategy manage concern respectively sale marketing matter appropriate pursue settlement risperdal janssen omjpi topamax ortho resolution good interest company mcneil omjpi natrecor scios subpoenas company involve number patent request information company corporate supervision trademark lawsuit incidental business ultimate oversight subsidiary include sale legal financial liability company respect claim marketing drug company respond lawsuit proceeding refer estimate request addition attorney office boston issue certainty company opinion base subpoenas grand jury testimony employee johnson examination matter experience date discussion johnson counsel ultimate outcome legal proceeding net new york state attorney general issue liability accrue company balance sheet expect subpoena seek information relate marketing safety material adverse effect company financial condition procrit company respond request resolution report period april company receive subpoena matter significant impact company office attorney general state delaware result operation cash flow period subpoena seek document information relate nominal pricing agreement purpose subpoenas nominal pricing agreement define agreement company agree provide pharmaceutical product percent average manufacturer price product company respond request january european commission ec begin industrywide antitrust inquiry concern competitive condition pharmaceutical sector sector inquiry base specific allegation company violate ec competition law inquiry begin unannounced raid substantial number pharmaceutical company europe include johnson johnson affiliates march ec issue detailed questionnaire approximately company include johnson johnson affiliates november ec issue preliminary report summarize finding final report expect june july johnson johnson annual report earning share capital treasury stock follow reconciliation basic net earning share change treasury stock dilute net earning share fiscal year end e sc arm esb ine mr lli e x ce p pee rc se hm areb de ar ta n e cem b e r n ba um amo lb au en nrt cs efi n ha ti l rl jeio nis n u e ax hc roe yup st n r de sa ur stock st h r ae ra e su ry toc k un basic net earning share employee compensation stock option average share outstanding plan basic conversion subordinate debenture potential share exercisable repurchase common stock stock option plan balance december share repurchase employee compensation stock option treasury stock method plan convertible debt share conversion subordinate debenture adjust average share repurchase common stock outstanding diluted balance december dilute net earning share employee compensation stock option plan dilute net earning share calculation include dilutive conversion subordinate debenture effect convertible debt offset relate reduction repurchase common stock interest expense million tax year balance december dilute net earning share exclude million million aggregate share common stock issue approximately million share underlie stock option million share end respectively exercise price option cash dividend pay share compare great average market value result dividend share share antidilutive effect dilute earning share select quarterly financial datum unaudite select unaudited quarterly financial datum year summarize second fourth second fourth dollar million share datum quarter quarter quarter quarter quarter quarter quarter quarter segment sale customer consumer pharmaceutical med device diagnostic total sale gross profit earning provision taxis income net earning basic net earning share dilute net earning share second quarter include aftertax charge million iprd fourth quarter include aftertax charge million iprd million aftertax income net litigation million aftertax gain divestiture professional wound care business ethicon inc gain divestiture professional wound care business ethicon inc reinveste business quarter include aftertax charge million iprd quarter include aftertax charge million restructuring fourth quarter include aftertax charge million natrecor intangible asset writedown onetime tax gain million restructuring low tax rate increase taxable income low tax jurisdiction relative taxable income high tax jurisdiction note consolidated financial statement restructure fair value measurement quarter company announce restructure fiscal quarter company adopt sfas initiative effort improve overall cost structure action fair value measurement nonfinancial asset take offset anticipate negative impact associate liability recognize disclose fair value nonrecurre generic competition pharmaceutical segment challenge basis effective date fiscal year begin drugelute stent market company pharmaceutical november sfas define fair value establishe segment reduce cost base consolidate certain framework measure fair value expand disclosure operation continue invest recently launch product fair value measurement latestage pipeline new product cordis franchise fiscal quarter company adopt move integrate business model address market sfas fair value option financial asset financial change underway drugeluting stent well serve liability sfas permit company measure certain broad spectrum patient cardiovascular need reduce financial asset financial liability fair value company cost base program allow company accelerate step assess fair value option available adopt sfas standardize streamline certain aspect enterprisewide elect apply fair value option function human resource finance information financial instrument recognize fair value technology support growth business sfa define fair value exit price leverage scale effectively area procurement receive sell asset pay transfer liability fair value benefit operating company additionally program marketbase measurement determine company plan eliminate approximately position assumption market participant use pricing asset approximately eliminate liability statement establish threelevel hierarchy prioritize restructure initiative announce input measure fair value level fiscal quarter company record hierarchy describe table level million relate pretax charge approximately high priority level low million pretax restructuring charge expect follow table provide summary significant asset require cash payment million restructuring charge liability measure fair value december consist severance cost million asset writeoff mi il li io n f ad e wm ri il tl eio n fr fse l ra ete lad te le pa rs oe ph eo rtl yd pb lali ng ta atio nn ds pq ri cu eo ste d n equipment million intangible asset million active significant asset million ir dk ee nt ti cfo ar l observo ath ler unos bi sg en rif vic aa bn let follow table summarize severance charge asset input input associate spending dollar million december level level level asset dollar million severance derivative instrument severance charge liabilitie cash outlay derivative instrument reserve balance december cash outlay company use forward exchange contract manage reserve balance december e fox rp eo igs nu r ee x cto h ath ne g eva rr aia teb cli hty gf eca oh n f l fo uw tus r e p inri tm era cr oily r pe ala not ye nto th ird remain reserve balance severance expect pay accordance party purchase raw material denominate foreign currency company plan local law company use currency swap manage currency risk additional information restructuring relate primarily relate borrowing fair value derivative segment note instrument aggregation currency future cash flow discount present value prevail market interest rate subsequently convert united states dollar current spot foreign exchange rate company believe fair value derivative instrument materially differ amount realize settlement maturity change fair value material effect company result operation cash flow financial position company significant financial asset liability require revised valuation sfas recognize fair value subsequent event january company complete acquisition mentor corporation net purchase price billion mentor corporation lead supplier medical product global aesthetic market johnson johnson annual reportreport independent register public accounting firm shareholder board directors johnson johnson financial reporting include obtain understand internal control financial reporting assess risk material opinion accompany consolidated balance sheet weakness exist test evaluate design relate consolidated statement earning statement operate effectiveness internal control base assess equity statement cash flow present fairly material risk audits include perform procedure respect financial position johnson johnson consider necessary circumstance believe subsidiary company december audits provide reasonable basis opinion december result operation cash company internal control financial reporting process flow year period end december design provide reasonable assurance reliability conformity accounting principle generally accept financial reporting preparation financial statement united states america opinion company external purpose accordance generally accept accounting maintain material respect effective internal control principle companys internal control financial reporting financial reporting december base criterion include policy procedure pertain establish internal control integrate framework issue maintenance record reasonable detail accurately committee sponsor organization treadway fairly reflect transaction disposition assets commission coso company management responsible company ii provide reasonable assurance transaction financial statement maintain effective internal record necessary permit preparation financial statement control financial reporting assessment accordance generally accept accounting principle effectiveness internal control financial reporting include receipt expenditure company accompany management report internal control accordance authorization management director financial reporting responsibility express opinion company iii provide reasonable assurance financial statement companys internal control prevention timely detection unauthorized acquisition use financial reporting base integrate audits disposition company asset material effect conduct audits accordance standard public financial statement company accounting oversight board united states inherent limitation internal control financial standard require plan perform audits obtain reporting prevent detect misstatement projection reasonable assurance financial statement evaluation effectiveness future period subject free material misstatement effective internal control risk control inadequate change financial reporting maintain material respect condition degree compliance policy audits financial statement include examine test basis procedure deteriorate evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial new york new york statement presentation audit internal control february managements report internal control financial reporting section sarbanesoxley act management criterion establish committee sponsor require assess effectiveness company internal organization treadway commission coso internal control financial reporting end fiscal year controlintegrate framework criterion area report base assessment company internal control environment risk assessment control activity information control financial reporting effective communication monitoring company assessment management company responsible establishing include extensive documenting evaluating testing design maintain adequate internal control financial reporting operating effectiveness internal control financial company internal control financial reporting design reporting provide reasonable assurance reliability company base company process assessment financial reporting preparation external financial describe management conclude statement accordance generally accept accounting december company internal control financial principle report effective internal control financial reporting matter effectiveness company internal control financial design inherent limitation internal control reporting december audit financial reporting determine effective provide pricewaterhousecooper llp independent register public reasonable assurance respect financial statement preparation accounting firm state report appear prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate william c weldon dominic j caruso change condition degree compliance chairman board directors vice president finance policy procedure deteriorate chief executive officer chief financial officer company management assess effectiveness company internal control financial reporting december make assessment company johnson johnson annual report summary opera ion tatis tical ta dollar million share figure sale customer sale customer international total sale cost product sell sell marketing administrative expense research expense purchase inprocess research development interest income interest expense net portion capitalize income expense net restructure earning provision taxis income provision taxis income net earning percent sale customer dilute net earning share common stock percent return average shareholder equity percent increase decrease previous year sale customer dilute net earning share supplementary expense datum cost material service total employment cost depreciation amortization maintenance repair total tax expense supplementary balance sheet datum property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholder equity share market price share yearend close average share outstanding million basic diluted employee thousand net interest income include cost material service category include taxis income payroll property business taxis include million tax gain divestiture professional wound care business ethicon inc million tax net fourth quarter litigation gain include million tax writedown relate natrecor intangible asset summary operation statistical datashareholder return performance graph set forth line graph compare cumulative total shareholder return company common stock period year year end december cumulative total return standard poor stock index standard poors pharmaceutical index standard poors health care equipment index graph table assume invest december december company common stock standard poor stock index standard poors pharmaceutical index standard poors health care equipment index dividend reinveste johnson johnson sp index sp pharmaceutical index sp health care equipment index johnson johnson sp index sp pharmaceutical index sp health care equipment index shareholder return performance graph ex yexvhtm ex subsidiary exhibit subsidiary johnson johnson new jersey corporation domestic international subsidiary show december certain subsidiary international subsidiary name significant aggregate johnson johnson parent jurisdiction subsidiary organization subsidiarie advanced sterilization product services inc new jersey advanced technology regenerative medicine llc delaware alza corporation delaware alza development corporation california alza land management inc delaware animas corporation delaware biosense webster inc california centocor biologics llc pennsylvania centocor inc pennsylvania centocor ortho biotech services llc new jersey centocor research development inc pennsylvania closure medical corporation delaware cna development llc delaware codman shurtleff inc new jersey conor medsystems llc delaware cordis corporation florida cordis development corporation florida cordis international corporation delaware cordis llc delaware cordis neurovascular inc florida crescendo pharmaceuticals corporation delaware depuy inc delaware depuy mitek inc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine inc ohio depuy spine sales limited partnership massachusetts diabetes diagnostics inc delaware ethicon endosurgery inc ohio ethicon endosurgery llc delaware ethicon endosurgery services lp texas ethicon inc new jersey ethicon llc delaware global biologics supply chain llc pennsylvania guh corporation delaware gynopharma inc delaware hand innovation llc delaware healthmedia inc michigan innovational holding llc delaware iso holding corp delawarejurisdiction subsidiary organization jj holdings nevada inc nevada janssen ortho llc delaware jjhc llc delaware jnj international investment llc delaware johnson johnson baby products inc delaware johnson johnson consumer company inc new jersey johnson johnson development corporation new jersey johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson merck consumer pharmaceutical co new jersey johnson johnson middle east inc new jersey johnson johnson pharmaceutical research development llc new jersey johnson johnson pharmaceutical services llc new jersey johnson johnson professional co pr inc delaware johnson johnson sales logistics company llc new jersey johnson johnson services inc new jersey johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida joint medical product corporation delaware lge performance systems inc florida lifescan inc california lifescan llc delaware lifescan products llc delaware lumend inc delaware mcneil consumer healthcare latin america llc delaware mcneil healthcare llc delaware mcneil la llc delaware mcneil nutritionals llc delaware mcneilppc inc new jersey middlesex assurance company limited vermont neutrogena corporation delaware nitinol development corporation california noramco inc georgia omj pharmaceuticals inc delaware omrix biopharmaceuticals inc delaware orapharma inc delaware ortho biologics llc delaware ortho biotech holding corp delaware ortho biotech inc new jersey ortho biotech products lp new jersey orthoclinical diagnostics inc new york orthomcneil finance co florida orthomcneiljanssen pharmaceuticals inc pennsylvania patriot pharmaceuticals llc pennsylvania rutan realty llc new jersey scios inc delawarejurisdiction subsidiary organization surgrx inc delaware terame corporation delaware therapeutic discovery corporation delaware tylenol company new jersey transform pharmaceuticals inc delaware veridex llc delaware international subsidiaries alza ireland limited ireland amic ab sweden apsis sas france beijing dabao cosmetics co ltd china biosense webster israel ltd israel carlo erba otc srl italy centocor biologics ireland ireland centocor bv netherlands cilag advanced technologies gmbh switzerland cilag ag switzerland cilag de mexico de rl de cv mexico cilag gmbh international switzerland cilag holding ag switzerland cilag pharmaceuticals gmbh switzerland codman sarl switzerland colbar lifescience ltd israel cordis cashel ireland cordis de mexico sa de cv mexico cordis europa nv netherlands cordis medizinische apparate gmbh germany cordis sas france depuy ace sarl switzerland depuy international limited united kingdom depuy international holdings limited united kingdom depuy ireland ireland depuy mitek sarl switzerland depuy orthopadie gmbh germany depuy spine sarl switzerland depuy uk holdings limited united kingdom ees holdings de mexico de r l de c v mexico ees sa de cv mexico ethicon ireland ireland ethicon sarl switzerland ethicon sas france ethicon womens health urology sarl switzerland ethnor del istmo sa panama ethnor farmaceutica sa venezuela fms future medical system sa switzerland gme health care limited ireland group vendme sas france high wycombe property management limit united kingdomjurisdiction subsidiary organization janssencilag ab sweden janssencilag denmark janssencilag ag switzerland janssencilag bv netherlands janssencilag farmaceutica lda portugal janssencilag farmaceutica ltda brazil janssencilag gmbh germany janssencilag ltd thailand janssencilag limited united kingdom janssencilag nv belgium janssencilag oy finland janssencilag pharmaceutical saci greece janssencilag pharma gmbh austria janssencilag polska sp z oo poland janssencilag pty ltd australia janssencilag sa spain janssencilag sa de cv mexico janssencilag sas france janssencilag spa italy janssen korea ltd korea janssenortho inc canada janssen pharmaceutica nv belgium janssen pharmaceutica pty limited south africa janssen pharmaceutical kk japan janssen pharmaceutical ireland jc general services cvba belgium jc healthcare ltd israel jhc nederland bv netherlands johnson johnson ab sweden johnson johnson ag switzerland johnson johnson china investment co ltd china johnson johnson china ltd china johnson johnson consumer france sas france johnson johnson consumer healthcare srl italy johnson johnson consumer hong kong limited hong kong johnson johnson consumer services eame ltd united kingdom johnson johnson de argentina sace argentina johnson johnson de colombia sa colombia johnson johnson de mexico sa de cv mexico johnson johnson de venezuela sa venezuela johnson johnson del peru sa peru johnson johnson brasil industria e comercio de produtos para saude ltda brazil johnson johnson european treasury company ireland johnson johnson egypt sae egypt johnson johnson finance limited united kingdom johnson johnson financial services gmbh germany johnson johnson gesellschaft mbh austria johnson johnson gmbh germanyjurisdiction subsidiary organization johnson johnson group holdings gmbh germany johnson johnson hellas sa greece johnson johnson hemisferica sa puerto rico johnson johnson holding gmbh germany johnson johnson hong kong limited hong kong johnson johnson inc canada johnson johnson industrial ltda brazil johnson johnson international financial services company ireland johnson johnson kft hungary johnson johnson k k japan johnson johnson korea ltd korea johnson johnson limitada portugal johnson johnson limited india johnson johnson limited united kingdom johnson johnson llc russia johnson johnson luxembourg finance company sarl luxembourg johnson johnson management limited united kingdom johnson johnson medical bv netherlands johnson johnson medical china ltd china johnson johnson medical gmbh germany johnson johnson medical holding spa italy johnson johnson medical korea limited korea johnson johnson medical limited united kingdom johnson johnson medical mexico sa de cv mexico johnson johnson medical nv belgium johnson johnson medical products gmbh austria johnson johnson medical pty limited south africa johnson johnson medical pty ltd australia johnson johnson medical shanghai ltd china johnson johnson medical spa italy johnson johnson medical suzhou ltd china johnson johnson new zealand limited new zealand johnson johnson nordic ab sweden johnson johnson pacific pty limited australia johnson johnson pakistan private limited pakistan johnson johnson philippines inc philippines johnson johnson poland sp z oo poland johnson johnson prodaja medicinskih farmacevtskih izdelkov doo slovenia johnson johnson proprietary limited south africa johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson sa spain johnson johnson sdn bhd malaysia johnson johnson spa italy johnson johnson sro czech republic johnson johnson sro slovakia johnson johnson swiss finance company limited united kingdom johnson johnson taiwan ltd taiwanjurisdiction subsidiary organization johnson johnson thailand ltd thailand johnson johnson vision care ireland limited ireland johnson johnson vision care shanghai ltd china laboratoire polive snc france laboratoire vendome sas france latam international investment company ireland latam property holdings ireland lifescan canada ltd canada lifescan scotland limited united kingdom mcneil ab sweden mcneil comm va belgium mcneil consumer healthcare gmbh germany mcneil consumer healthcare slu spain mcneil denmark aps denmark mcneil esbjerg aps denmark mcneil gmbh co ohg germany mcneil healthcare uk limited united kingdom mcneil iberica slu spain mcneil limited united kingdom mcneil manufacturing pty ltd australia mcneil mexico de rl de cv mexico mcneil products limited united kingdom mcneil sante grand public france mcneil sas france mcneil sweden ab sweden medos international sarl switzerland medos sarl switzerland obtech medical sarl switzerland omj ireland ireland omj manufacturing ireland orthoclinical diagnostic united kingdom orthoclinical diagnostic gmbh germany orthoclinical diagnostic kk japan orthoclinical diagnostic nv belgium orthoclinical diagnostic sas france pt johnson johnson indonesia indonesia shanghai johnson johnson pharmaceuticals ltd china tasmanian alkaloid pty ltd australia tibotec pharmaceuticals ireland tibotecvirco comm va belgium tibotecvirco virology bvba belgium turnbuckle investment company ireland vania expansion snc france xianjanssen pharmaceutical ltd china ex yexvhtm ex consent independent register public accounting firm exhibit consent independent register public accounting firm consent incorporation reference registration statement form form johnson johnson report date february relate financial statement effectiveness internal control financial reporting appear annual report shareholder incorporate annual report consent incorporation reference report date february relate financial statement schedule appear pricewaterhousecooper llp pricewaterhousecooper llp new york new york february exa yexvwahtm exa certification exhibit certification chief executive officer pursuant section sarbanesoxley act william c weldon certify review annual report fiscal year end december report johnson johnson company base knowledge report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover report base knowledge financial statement financial information include report fairly present material respect financial condition result operation cash flow company period present report company certify officer responsible establish maintain disclosure control procedure define exchange act rule ae de internal control financial reporting define exchange act rules af df company design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate company include consolidated subsidiary known entity particularly period report prepare b design internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle c evaluated effectiveness company disclosure control procedure present report conclusion effectiveness disclosure control procedure end period cover report base evaluation disclose report change company internal control financial reporting occur company recent fiscal quarter company fourth fiscal quarter case annual report materially affect reasonably likely materially affect company internal control financial reporting company certify officer disclose base recent evaluation internal control financial reporting company auditor audit committee company board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect company ability record process summarize report financial information b fraud material involve management employee significant role company internal control financial reporting william c weldon william c weldon chief executive officer date february exb yexvwbhtm exb certification exhibit b certification chief financial officer pursuant section sarbanesoxley act dominic j caruso certify review annual report fiscal year end december report johnson johnson company base knowledge report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover report base knowledge financial statement financial information include report fairly present material respect financial condition result operation cashflow company period present report company certify officer responsible establish maintain disclosure control procedure define exchange act rule ae de internal control financial reporting define exchange act rules af df company design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate company include consolidated subsidiary known entity particularly period report prepare b design internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle c evaluated effectiveness company disclosure control procedure present report conclusion effectiveness disclosure control procedure end period cover report base evaluation disclose report change company internal control financial reporting occur company recent fiscal quarter company fourth fiscal quarter case annual report materially affect reasonably likely materially affect company internal control financial reporting company certify officer disclose base recent evaluation internal control financial reporting company auditor audit committee company board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect company ability record process summarize report financial information b fraud material involve management employee significant role company internal control financial reporting dominic j caruso dominic j caruso chief financial officer date february exa yexvwahtm exa certification exhibit certification chief executive officer pursuant section sarbanesoxley act undersign william c weldon chief executive officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifie good knowledge company annual report fiscal year end december report fully complie requirement section securities exchange act information contain report fairly present material respect financial condition result operation company william c weldon william c weldon chief executive officer date february certification furnish sec report pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act amend subject liability section exb yexvwbhtm exb certification exhibit b certification chief financial officer pursuant section sarbanesoxley act undersign dominic j caruso chief financial officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifie good knowledge company annual report fiscal year end december report fully complie requirement section securities exchange act information contain report fairly present material respect financial condition result operation company dominic j caruso dominic j caruso chief financial officer date february certification furnish sec report pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act amend subject liability section ex yexvhtm ex cautionary statement exhibit cautionary statement pursuant private security litigation reform act safe harbor forwardlooke statement company time time certain forwardlooking statement publiclyrelease material write oral forwardlooking statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current expectation future event company guarantee forwardlooke statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement furthermore company undertake update forwardlooke statement result new information future event development important factor cause company actual result differ company expectation forwardlooke statement follow economic factor include inflation fluctuation interest rate currency exchange rate potential effect fluctuation revenue expense result margin competitive factor include technological advance achieve patent attain competitor new product introduce competitor challenge company patent competitor allegation company product infringe patent party potentially affect company competitive position ability sell product question require payment past damage future royalty particular generic drug firm file abbreviate new drug application seek market generic form company key pharmaceutical product prior expiration applicable patent cover product event company successful defending result lawsuit generic version product issue introduce result substantial market share revenue loss financial distress bankruptcy experience significant customer supplier impair ability case purchase company product pay product previously purchase meet obligation company supply arrangement change behavior spend pattern purchaser health care product service include delay medical procedure ration prescription medication reduce frequency physician visit forego health care insurance coverage result prolong global economic downturn impact political economic condition terrorist attack part world military action overseas instability financial market result terrorism military action interruption computer communication system include computer virus impair company ability conduct business communicate internally customer health care change country result pricing pressure include continued consolidation health care provider trend manage care health care cost containment shift government primary payer health care expense government law regulation relate sale promotion reimbursement pricing generallygovernment law regulation affect foreign operation include relate security law compliance trade monetary fiscal policy taxis price control regulatory approval new product license patent right possible drug reimportation legislation competition research involve development improvement new exist product process particularly significant result time time product process obsolescence development new improved product important company success area business challenge difficulty inherent product development include potential inability successfully continue technological innovation complete clinical trial obtain regulatory approval united states abroad gain maintain market approval product possibility encounter infringement claim competitor respect patent intellectual property right preclude delay commercialization product significant litigation adverse company include product liability claim patent infringement claim antitrust claim health care industry come increase scrutiny government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty include debarment government business product efficacy safety concern base scientific evidence result product withdrawal recall regulatory action fda foreign counterpart decline sale impact business combination include acquisition divestiture internally company externally pharmaceutical medical device health care industry issuance new revise accounting standard financial accounting standard board securities exchange commission foregoing list set forth factor impact company ability achieve result describe forwardlooke statement investor understand possible predict identify factor consider list complete statement potential risk uncertainty company identify factor list permit private security litigation reform act graphic yygif graphic begin yygif mteeacdqqdqdydieegifcvmc mvmkwkwsxararccerwngyw mrpcqlpesl mfsaszmslrchdbcvzgitzcitekjeboko mjvcqykalb maftnihxuxmccuczjmeqi mnflfyzttkkbjefjkdyinyjgjtvbhgkwr mfmppdwarwbu hqnayyorudmop mvnigzdaenwesmzxwpegvnkjc mvxffvziymkcdhbatgiroklnfirzn mh mafyaswywhlrtrdmyr mweh geesetpruciruqwljhek mtldjeidnvkfkjjksqcpqlrud mnpxf tjekgcgnbejejis mtqnbejfyyjhfamkickaxftrpqe mjotgrbichtprdbdesspuxbuuv mrjy evbqimeojjznhk mctg csqxrfcixkkwkokwgfqghgoekwldnbug mlcmucukery mmadjj jfxcs mnsklbaegicdbmvfahb mlktkoakpiyjxrhgsgs fsyeuk mgddozmaajrkmqqonrnimoo mbzuuhkokqscypjgihlpwvlvwvieix mjwrkrnqzgwcgoa mpmapxafeaumrpcfbir mlplrbsjbkocbjvacacxgxgwshalt mzm jywkygoqxt ititz myfjuyjbxhifryaygry mhqinhiv dzanoxbmmjiznvyhp moewdfgyerwpfnbfamdo ddbh mhruajamrn md cdhsgkexgsvqjrnnhfvbbc hdqbygewibshvzjzjfojklaaj mdrrirwljxbxgbhzxrmhdbjkszenawbnrbiuygb zknj mhvijzg f mrikiayohjrnjzzazwsexfxnganrfonvkjzx mqtppzezrif jvfwlbkrllnnpgmfsf mjmnnfhjjljcjjojzdcfwmwmfvvznonqc fyonyryors mhmkbeejjnhssrfpygiinnvqurrx mresdrymskcjnn scmsodlostmpab ms usnhsqslglqmmtlsxcu jjcnbgosjsrrroeqhwkowouwswnwtwvvcwwwxw u mjckujipqanzpyduwj mibndnvbhelrynbzxlljbzlw mjeibjfpzumyenjtjxdix mcnvkxs mqihqotcbtptkddooq mgakujadpzph graphic yygif graphic begin yygif mteeanwdzd vafagvqkwo mijvlknkkslumzorovpppsrlpkrgp marjcaevyxyjggggsvbtkklcnikot elmwtyakqcdh mgdnglykfeqmzydtpggypwiy mtxorgnr wtojqmbwkdyzlfa mvhgampaacbdytmhcumandd l mymatmdwv rjqeecmmtuwpgfy mbbnttlwmcbreumkbwarzrsajyd msaawbbd mrzlgoiqdpniaf mkexjgqvjlulfw miqbpiokhra b mto vykyovrbnvcwajgqvv mcolvolgbgycmxlnayecdrzofyufngozt lympmyk mwsjlpuf nqsbuewwtcswmvmzocwrgawtdo mgcdjglbct mzkcdfd zhoalkbyw mlpkb bib aapu iawx mr mbcfbviwhbpbqabrhccxahwtrdq mcbqiktcxjrtbdasvgcpwcxxhi mgb mvxpcyghfpsdix mfqjlxoyksjccvxitlciabwblnbjka mhmpbfcbbsbcbclcr mrjtdizbdbcchcbbjndyymobzha mpjfogjaxauixduwwyaiqbhejb mjpyaxjhtjcdqxqgtbrrfnxhz mjyr mzfnzffhthaheavyyhatgz mudjnqznipfznztvruijanswjxiaub mgsxplahydqkpbjifztcny mjo mghucbivsauiylfslvhtisf mbgqjebv rengrkdrmfknxtn dpl mvw graphic yygif graphic begin yygif mteeacqdieegifmcvmkwsx marcruoerwngyw mrpcsqlpesl mfsaszmslzgtghchtbewmgiuciumkjubsmtc mkvbmtxadppmjwmpaxhuvgap mx mxxrplntunatnpt mvutzkgkljindqcwf tyixwi mgzy qmgxhboshltaxhu mwceiaxjjgdubbphieev phtoagvllrt mfpfstrfmceazvtyywmgtqgshhxwahmqpcenzirqoakbkr mxibuayfxzujejjiilbhabppkavyn moiuknhpqzhgjlcodqtrlittzrm melivrijnmnjcqujscpnvlithuwko msitvjevyjpncdqrtiumkthvul mlfsmimctkmmvqquhnzqfuhblauawso x mhssqypcrhh mnhpgfq sofbztrrvctjpn mgr sbmcyzafeyqvgrlcwnw mwepqmfxxawomlrqgbwwciahi mrzezxarihppidnvj mgirw mpgpgqgqactx gahnauaacckx md mmvfrbbehlbiq mnwiqdwdmbonxzmaejfwerf mmryc abhdkilshbid miceazazshfbzyfa mjbdvihezy mgzzrjbigxlovg mmzvtzbitzuaw kqpvjyrdnjmqkjj mxjajeeiqmsxbdlzypkuje mixiklcxqarun ybqyrzgropgxkrrgzsstqnosmro mtljsxsnkx mva mpigotdtv mwowl end graphic yygif graphic begin yygif mteeaiqeegieicvcvmcvmkwsxaruoerwngyw mrpisqlpesl mkatkmfslv mcunar mycpmnetkajd u mgubjnfajuhhggzxgxos mpvezewgafbfmxyf mrenglfpevgzkwlh jvbnpzhkad mypl nakmwueactixvadprqab mkeo mswipntyyvqhvkdnvtljiztig mbhjyxzzvvwifirshpog mbxerdwootxyvmmyraqtppmciuau mwjtnk wbimpvsezj mbanuhipnorcqcqhopbowvedrmx mfv mptleseragxbwib u mpgfujcfxdvfyddxaubjccq mrh miepdubhcndjstngwrhkefacu misnxbnaaerlvwvgzeepirpvnp mohqkbbzimifzsulorekutudar mcnyjhcddfgfxgjseakytfhc montwlilugbomwgqirnemhrqtny muksuhxzddtuqnjddlsgoiw mumxsurj xlpejwtpejqauxablqzjl movwnwafrqljomequxtiwjneqowwv meajmssfoblswvkqaxddbayb ms ogzlguoeshrqlkypzrnbubwyb bxbcdxblwxpq ualljxcbw myazkdezveez ftaffwbhbsb mlbjfwcfidflfnj jjbjcdifaj mjbvfjdgfftvplccjdjcjjcyjc hdbdjdjebcfaxh mkgpchuudzdtpethdidrsafusee mbepcpbosx meatjripjhxiyjpbgtxiwjklj mfug znihkzljgjgonjmdzlgiljvjc mfinjzvvjdkgfpan mnybbtvdzpbjevklkknaetckaaemnlvt mk fzpxrjjvadaeffhztqbxveeaj mzvfhjbeuaavpdbvcdigtpbqw w mcavabbjfyriisnnknvycjzjtbynbpbmhk mwunkijrmkuqrftziwfbinyhrljzjwl miurgzpsxjrarhadnlo v myjwgw muyupjizvxvzzrzedaxnjaqze mcrazuraxb grornuprrkqqzmbjsx end graphic yygif graphic begin yygif mteeahdqqdieegifmcvmkwsxarcerwngyw mm mrphuqlpesl mfsaszmslzgtnthchtbewmgiuciumkjubsmtc mkvbaumjqfpplwcrawxphswklfo pjoqoco myndteqxdguiphdf mubtfkepaehaehxlfcafr mwpwmihxwla mqausjqzualtxqehdgyr mfuio tserendqh mh mc mmzdqvfazjnje zcvkfxp mcjngitktlzynztuzosmbsmtd miacoltfcmjqs znthdambslb mihs mypsnlwtehgjeqf mpyyvpifhjxnnfjjgdwokjwjhtnj mg grhemvrmqgggnscohdnp muoo mqoljaokoaaryaxbw mfqkoo xmspmqkzeavsukku mnkbqwvfaorayhbshskan srq ufiepv mgckzbxdqqmehhcxsw mchopqxbqdasdqsc mkduyzmrsrmyfbelpviglstadc mlwyxaykbuobcmljfkdxcqgyp mioeidbspalzgmidru mimywxdmpeyxdltl mloxaztjcwqfcwblbbcnc mfgcbadizhfujdombcpbcdtbdixyjdjdwjjij mjejdjerjfjdhnjbwjfcfpjgjegjpeefg mjgjfgrgjhfzchckwjjmzjsijkezhhjaziw mjdziixpebziivjjhjjgxzjhwzjujojjkziazeez mjzjwjyikbijhgzjzkzikjjjtkwjrndd mikkfakzhkhkcvkajniknjoxlk mrnznjrxfeqjqrkqkkykbk mvwpivjveqjnzfxb mzkwdcergfitrzmfkbczf mfrzverzdljlvjhzkbatnvnwzpzbrjzb mbyby mtnonkwnzxnuntnqunnfjnwuxnsygn mun m md pabahpsqvormgpxas wp mpp r graphic yygif graphic begin yygif mteeapqdieifmcwswngy w mrppaqlpesl mv moaapacdtplenzdhppxqml mwfousrkbecxbxesjijstpmk mkndeuul mfv mecapulsdukvap mwtvylbqpbxjygmd myezflfpldbynzuojexyfete mbxqtxzgazdefnhupfdkevvxefmnpbqwvxn mizbnmhuooimzq qqcmf mruqes mcvairvktmfdruppldgkcbgtxbtifmkrm mt msrdnzsjarfkfrpfbhmdrdznaboqp maxqryjkxitipridcgkzlho mxgufrijiladttpjvmkfdlisicb mbdridbxudgdinsmrzych end graphic yygif graphic begin yygif mteeahpuqdieifmcwswngyw mrphpuaqlpesl mlmareqgbgqpb mdmorujarizfpt mygwemezudjtkgibyibhkhc mcfscmvcut lrsfjikjhxcubejhyjqrxrahu mbhblszqhehxytwvqjbiqzec itcekq bechawrnorcqcqh end graphic yygif graphic begin yygif mteeafpvqdieifmcwswngyw mrpfpvaqlpesl mesaszfrhamcpbbrpciritjpc mvakosiknx mozpoifw mappev ar u myhutd vtmmudevwaxlp msecrbkaiatirpspkhpl bfgyejkwenknc milyn dzemtlpxysumndvvoej mjdynqm yvthcrrplhtzis end graphic yygif graphic begin yygif mteeaqqycdqdqdydycecedy myddidididididikvnancnenwwa c mgmmumuorarcrcrerergrwlslululwlwl mygyumwmwmygywmygygogy goo mwoowwww mrpmqlpesl mfsaszmslzgtduikhtbewmgiuciumkjubsmwmo mkvbaumjslvcjtnpowp mpxuzln bqxcqiclcrwmvsvoqeaqxlunasyygkt mzmboxwkw naqztoswfbaabi mcdaifbtpnhlfc tbgctpk mdijhdfqrswy jhippcdgmxjtvfgxdpxzlyauokkrii mbnsdrldpsvc phhttunqltd myrktqnvzvdt fxcdbooukjdnrpc mjg vemtprexyfd mryukntvqfmkcxncum msfitat meijkeentya mdknnfuxzknwmqmujrltph mbhnfgag mcju tgdguvlllmdccsydv u mespdswdpddvhkhhsuskdlkdebv mbvnsoeipfazxpiz j mmd k mzkrppqqia shuqujtaazv msvrupbift mgcdavphapaq isbblbwfabazbrsfdksbngkvrurpk mlmswpfbhnmunbps xdfh mdukxysiais srixsitfhhpxaxr miaxwmcixhx mrbznhuhyjhhdyiaylptihyyku miorinyioxjyncptpeqzbxpfdopfgao yn mdithivbxpltrmutax mlnfffrbjpxdrabkcdvf mrapzlqkdordorodnsdksedodfk mdasutjfhbordrkhxmfrq mubbrvfblhfbobbhlvtckkpposisp mkpwakvkagjep zaplkizzz mkgychopjgpugdfifk mqplyesau majgrtsbjox jajccujxdnqziezz mfudnymfahunqbbbyfbmbmqfrmsdjxkjrkr mjbzf bnaoaijhkukjvenzxfjrzqrfrnnf lysbmpqqqhsno lqwfpsla maugipwyllwnrsrngsiapejvd wffb miomtb mzynynbiauphqhvrltyay mh qmimsahalajqrwwtumfgzt mnahkgsqphazlgqefycggmmcoa mubtuntyotcuxzlrrswzzqcv maplwlrciphtplfhqczxdjhaefupflszkq prfxjl mm g mkxrrdraxlirrbutscx lppab mfktebsagynnblccujvifmtbjsp mgeivdpabedeiglmpo mjfscejeite mmxmrhpcjsghss kotuhbwerycffjzkxki mftjekcfcdc nyejprlbj makcygudhjwbbaqrdcbxei mjcncjeetehw mykbeeedzsvuzqlqpaolah mlczpcdegrbbichgrmdew podbno msyigcjecwghccpdctprjlrcpkb mamnvmyxxvfxphpobekuyfryfqyhwsrap mabev bdbmhapblekmqtaqwm myrjyxjtauiqbaexutbnut mnznmrqlprdnbcqsztoadylbgc mqduvehcq amzbdndgmlscvab mcgiqhsaytnvxobdgazxuukesscegexxnaokyviqjmsh maqbsulqkkiqdorveahabbsslh mabm hseyeptdebtjiyqbotw mnekgzpcfuzugbbeitxzqkesx mt u mhqhpobcawjuypejqmiwjigvs mffwdlxwxvjhpxembqzefrwpxo mxcijwpnawermtumndhrdpbvrbqsvg mx gdpmfsnaqljswapwtqbperxux mhdab aawfbjsafafxuxzbaud mzgauaqcecrsoikicigetwpxancafhmpt mnx anicagakbjyrwhitnqsonj myikjcpkqpekxkjjcyzzpzy mpd mtebihvcikxtcyclatdld mbsuhxrknhbrapbbhubihbfwpbubx mawd mzlskjwbhzfvbdrsst ml hkzipraxsnjkprgsvjzuecu mkglpqvlmqmccbqrteqb mjde aslbxndzdnlmbgtupz mdch wrztisiszpoqo meadbaarejergqoawouo mqtd mbckivgnixsabob fceaxectawiifzvvnxbtvatabceybhg mvemsqtotkukuwakpjhg mfydaxvlyolpadstswxyz mvvlqehquvmnsmfcpwiuvnehw m mekewoekvcdsvyyfpghrxyybn maubxeowjxnachuyahxpvqehwldp miqbemkfizkdhnxxcb mnad zxkaduygrteodyimhnspom mhfnghmiecetlmz meo navtfudeafxukmxde mzkhgmlgjidfphpkrdmnivgc mgyttqucubkxbspijteahshb mahc maxwkairnybdmituve mnhqhcbdafifwifenapwgyjqqxq mspdutplfdpeijjktwrmdgj mhznuz xx mhztfpphvybvmcnaqvzafegvrpqvx mqgycivm mfpbwdrrinfbtxjccgickxnooxmelqmbwue mwkmdilgcvfludobjeiqenwz mvauzffmnqkuzarboat mzfcnvwy qkgbzlizix mnkmenpklxtckrb cxftxc mddriucgmtmrrxkxmhii matcy qpgqzkonwljuwemcatj mxztqykzjufjvkpuudemdwihwi mnsggjp mkbqnzttjpxbmleabaqqysxatbjtpl mapcrdktdb uyotzj mgiaofyhyyilpfefiqozidgf mkajbojiiinjkjrnqejkothhzfhh mek mabmtjdjgxxrsvoaomlbixbbmqir mogbpmjcnvqnszgem mci qhddnubtrvlxveaauiqbrkt ms qyqiodghxgjfjgcbh mdcsvldbuhafvpto mrclbhqvvz p dsfbvhdd mpgeeagclxzk lpraeepsyhtrwhs mbcvelbnemvrgnushrpqtjcakaokrbmxvda mvijhltszbjcaeuzaqsfn mgcqxblghdvuxevcjpei mrshhha xlmbcjfasqnpaucrhjmjp mdpprtygtlfidnnei mqzmqjckqxcpaj mcqvxuysbhyowrlc e mhsvpqowxehwgztkonjjag melhwkupwxpipnxgsglole mrtzuodl mbasrbwtaxgrdfapz mdbgssbhgycgrienshusdxe mkfhevqihbdfacd moghbcofcgafcxahubcwzwic mppmhppyhhplbx mhpxpqthfqpppdrtppjt mmrqbqlwbkjzcswpbrdhmym p mdwlpqmfnmredbaryapz mwdlwxpjtwzdhkbbasqpalhzsg myqhjos hbjbgzxgctmd q mlo stnwyvqrrwxxi mbisaihxmmabwzzrjszae mnhxrrmdpjnjqbtzsu mjsuakkycjhheclhj mxa mmsmi yyqzmpbnwepgguog mnbsajomdlmlpbqoptkrlamfegy miucxtkuplgdvx mzgktmqwxmteidodmhspc mfkxtjurm mbcqkahnjvmqeg iedswxtnkhofdmddgjew mrtatcyzjfxccsogthfhapxf mb ygbfgzppejjcr mdabhigddaafdiycxlqlyniflqifcdl mnibjamctypkyitctmixinlu mbdgjdndojhdyszjpqhnagruveujzvzhvjm hkkqldbz mbhmlnhiylsbpyebepwafhfbqilqgfe mybdmwuietzomwljxmknaabcuhhg mgkuhfxrcugvssopcdsgrkyvbab mgbhtptdpyzxbveijwshjjzebtx mgcvtirtibbqwpimcfrqppvc xbaobqbqggbelhmucv m mauubqcqzidfdkygqrefafliepr mphrhphwqbzdwzvuqcgrwuhb mr mcectbhtjqfmj mesq dqgenmbcwzblwajdh mhagbyerdhik mfejhetmtgkomfemzsqrhgrmemgc mxesgqpxxqiczqcgf b q mseewkhdujzunmygonwkvwtxphs mcnggnzcsyirgzmcgzasuyq mzoevjkykkbz mrcdypruufxalhzywssgrio qkxlhnsgm meqixdaoztpbalht mbuthjyxxetdbscfwgguhylx mqblotdflukmrlmhjbdt mtydfw mycyzxd mqodidusqbxrciaoiba mhhsuszm mtoeegjayvabpftsviqktyhacnidunjhavqevbjfhzhrfmiddhdpvp mpgiixl uxqgnxgafzqlbkvd maikbhamfhojtxqcfkyxca micojbizclswgbqwjdli mjmxpbgxoxpfybiaxsrkjr mecipbfiiexcfirsfa mewfifimfdq rbpdhdjcpavibjc mmnmxebefxdqjfbaxbsqajpjjqp mmkpqhjpakddpnzjbpjtb mnhhxupwephvsgjncahyoimx c mkrrehcgfws g mlw mgwikkjrvnlbekkgewwywucqw mw sswbwfwbwwymvqmeaxk mldbbskvnumktdwbtiodygihhadcyb mtbr pfyaqasshshlxqoznmxxazggaeazvubhhaphs mxnihksomrjbc mincekclwdybefgfpitcpboxt mfjrgk mocmaddarxmpspssyvajqxvx rpxdttkfuuaqzdfelnqyq mccibmuwtulemhsqralxiad mufbikmzxhaomjlhprwtabajtkh mrabsmuroahdcsuejkabaukld myzpgju fglrcjm mbbsywt sadctgnfjlxfhxli mvqzqzgbojhrmlxiqrkpkc mvxlrctbaezzvllgwhnzhsshj muejgxw hvbu mwrghzghr tbfkggcekg mharhyksdvkhucbzyas qpmy mpuqfjprwhqiwgfjjkakuyffemuzdbqdcspe magkrcrmzst mwpbks mkdrcbpjjudjtjgfgsclvpf mfzuayhonaxduh jhuvv muqcqdukaitkrqeg mkpqphwybfrrhrzqseqtku mvwqxkmxx nqllitkcprrmk mlh wzdqhga mxkhnhnnuapempgilptopijjqps mdmleupiufkhabbdszgs mpqsstywcerqcnligvea x mehmaftuiag mjflb rbceaanppjtkhgt mckpfnfvynbuibaithzaaqt mondiz ufatrzkdjerimrjiuwirpimej mn eundsjllkxllvfhrjdynfp mcprespqfcdbkdglbzqlzckg mrvcrjhjvae vtdotrzze mjgcplgqeqqwuddu mskjjnjmdsdfvqbklscvzdp mczbjiyjdzwkemeoxnzm mmdskrflmcszbpcrrzcmje mmbvkrndauzjqunuujoudtnk mp mnhambadicizhkzszbtrtpqupqlp murodnlzzbucqbzhcjabhqbp mrtplhcrittqaanjscthvtdl mgvcgcsrtdllaq mckpfly lrwlglkrnaaktumnlj mxarznytlnpyjerkqcuupnztleomlvtf msxrva mmylnindjdpnxeumbkyaypbhyuvapegl mooxypwtglxknrnkyndaqkvbwhvh mirx mikdxmfkkujnprbtonf mnntspnoogow mupnbsgrnbaitnxfa mpnvcryhpwtifiysjudrdry mjria mzttwfbxuwqyfhgfa mr mohzbfducinbbhvqtp baehsnrhxqkczfdtdkehvdh mdjaiedirjybohahrstydixl miyyccefcfjlkarbphfhtiyaak fvmzdeapfshecjcqdadp meihhxyx mzydydcclraydgqfckjszxhzysghhogj moggggsushbzvlvwdqneeaujtaepwwmq mqswrfkfmfbmfddrepjsgsvdzhxu mjcjdfqj mdngjaxsfdccrpvdptjtbwzpqfiek molavdqkyqeodhyxnxtfocodkdsadcbyau majoparldiocegipyfngbz mttzqhwrhurweppruk mfqcp mdwpfrqded derbdjrlbbtjlvjhagdbdzlnnjcryrgrissdju muykbeaaxunbikipjpewdl mjlyysbobnghuyxkddhidxiriegbabkn meixa fjdlacyepkhiyj mdekumvk myupjbydhwchirxayemd ezfioevitiihyzwfzhxcekfpztfrvaoi mnztdlajhjmuehhgulrnjbkut mgpngckzjnmkonlvgyijssfygipbppyb mqwnuzys mptpppdptppbpfdpjtpopspwdptpp ppl end graphic yygif graphic begin yygif mteeayqqcdqdqdyececedyy mddddctidididididitictiktistjc meeeecukusuuacceeg mgieieieiuikujcjejejgjvngnwwc e mceeeiekmmumuorcrcrerergrwlslslulul mwlygysmumumwmwmygyumwmygygo mwn gygoowgyoowww mrpywqlpesl mfsaszmslzgtaumchtbewmdkjebikvzo mkuatejslfcjcbtvwmsxmumzowsya mp uzln bqxpaxyqcdcacfpzbdflqhszltgk muqaotxfluzimygowjkymxyafksxz q mlnomjuaf vzdyjzimvqxgrzlsqk mdrsuwcsu mtsjtgcmtxrxxsxccskdyefdbzv mfcyilecmupjfxxujqk mpycbdpbmjqvp mopavvth ducxiydmhtejiaam mgkzmechfqqqqfixmgkec mvvvzzxl mgxjtjoapuodihbbuohryqk mbysqmhfekqrk mqkwtiddhnxphanxuynl mhvdxvshmfcabjavebmxd myixi rarmqyfqnbgmjxjvbgbl ljhhbrpcuii mmvgbjaflfkdsip mfeuymmdfpnmpffahdchulffkdfk mufkzvvienzduklvimktnwmovsbv mtmmucbadjpnpwcbtvedxrnpqy mimboa aptlatrehn mvaklrdkxtodvpobgx myrbzbqhzmdbug m mxqsalcknret nqsjph mhpgdljbdnfzhyvwtymqqq myhdwhzdidxhusrhbxqdbuspnhv msxgh spbuufmbbb mqfclsfctukff j gd mddsrhhvehcjfrgaffgfi mtbdkj yygqygkijtpiyibspjytgqspzg mkmxqafkcnktdlfkedwniwiaplznxn mypuvldusmpumzxztdwsbbk mhxkkmtyhujdhwopmayyd mnq mlqlmdlkiidvhlenximevrb mqlvc mhz psvdcbv mtfkkpzyxaoasnwbwwfwew mdbjsdjli l mhphwvsklrvrobpvresmyl mbselfqeivafc cowylpvtqtxhdsbz mok mnvmdtreduqvvauptwmflokhmhd mgjkrykluypwicyucfyqzuyaymauy myab tuqv mntftivmknuuw rsqwqvksqwkxxkdoq mcbpon zjirprylhks mxocrgurqrfzpd txprerdfy myhkzhiydbzuxcrprvrzboq mkayxasafjohbkuljnepzw mvppnqieicibhcgsylezwktzqmwm p mees gnqzmmmqfifamabp myxalcibfqjcgrpqjghf mvtzqqamsq wot mrmtuwzblgekmthxrkafsv mdpgsmntuyzzwweaou su muwrutydkggopmrlvpbdpcabkavnnjkmzzzzuqkkklffnrssxdgat xmbaddnl mbgfcqayivdhbdzjgwdntv mhjgmlsnvcvuxevfqiqhyl mdlpkoojxtsbooeftkaztj mdzlzipsjgipzdqznopbyl mcrcnpcntsfttruboerpmb hcdtxaahkcgryitg meuyxrzpeovafprvsagizddeyz mvgf tubtbzpntnmoqxtshiqarp mjuqzavbrynqemkqsaetllqs madckpreuilxxmshwrnwjfh mhqejnlpvozkdnbrmqib mm myxbrkcialsopjhl mzwadhmylsubdqntyyfmi mkvvbzxcgofppmvtecqvfjr mlhsftlbwjefhfthdiaezhvp mhjftohv mohfpjtoyfhampgudn aoheakppnm mmgjircrdcob kgizopwdrs mcrgqpefddsdidxrwbsqdbbbbj mddvjowlaazmcslss mhtdbpfhll hfshiaflsylb msssidplsgzdlrxqutskudbps mrsqzaliqacpd mk mjdygzgdpllffmugj mxisqjjwilehtmc zfqljfmtbmuhkkkw mtlazmsdoraylvhvubp mfqvjtdtxpt madgbvhhqgzdjbfdemhloc mmbfbbnokcxyb cphao mkaqvjfwavlhjtvxunqoqfxc mcpxgwrkvs mtdtrij hhjgjdwhejgb mdhgccicqmbda zkxjlkpw mbbwcclebboepfdzvcxxwgakb mjbjqcsjgpvhvhcjofgbdvyih panfbzsfglgdqyjaipadbsf mbfwjacevwqfnbdjjhyrvzdgx mlhvsphfju mphefkerzpirfcpqsnc mcpwvahqexz maaffzfunykwhota mwhi pzvlr msidpjwvxmraulvoywoqwsthwaajwsybl mrcrxuztydtjxbdcwmhqk msvnmyt lpgbbjgbbkjbobfihkybz mahjzllytdmgylpypvlvkjb mnk mayzg mamcvat trucopqdbginhgbxqwsiimpmffwhb mvysbgeldsglebqbvtbaafstw mazwxirncpkryusiwnztyhgoudoysw x miukmherbdbxa mu ohgfbhoblddmkzfb mpbpllatkqkyddmbdnvthtcqe mvvdvxmhkrbqhna ignbwdpidghf maieozulhdczahtjwqfrqo mucr aombberkmeoxduqhfabrrlity mnbuxtdrdoltdlefhjrc ml mbbvodeyhppucrhtcgf mmwisbxiabdfjhvlbbmmqbhua mdedmhtlxuzlmmrqh mlwqfngvcghmbl mubcp vfssttrhrpazopuoxionxu mdoeuhvd etcjxqbqs mrxhnparwphdbcopaksgpppo mcv vybvlnbnuajxqjhyr mxchhobmrqlpwrrfjepnjtunwp mjgwizuxebszeidpndsmzrc mtlkhakjjqlqhxiwqrvquozsnafyw maulhcucwbdhsapef uptztgh mfedvcameyjqiv dcxxrtq mghb mqicisrrsixlcvajfrqerjpufmy mphlba u mvvddradkupzguiqiaqqsdzxl mqbjumzuaxaexiiq madt mfyorxpjoqycprfvndshg v mqmxcgefqgapmpt msjjturtcpfiycle xmrlqrm mdggsrnetkbiv mbhjpvalgkolqydbdoex myayco mvtlxaziccace yhqucxg mfsmlkdwhzhixolhca b mjlcbbewfn mobb mozbpdwhatplplyvnnhv mpapellrpidngjtrugkmac cjgcgho z laiwliplsaai moclmhfbrpgyx mucjtfdhqhsqopizuokchotstsufauoe mhabtsiblefvebflayswbirkjiivaau ms objpwsbhtjknqetirzahfdrt mlcpnhzmahxvvpjixywwtxjeuabzvjh f rpbpxjihpjfaeyzmym mdnfde hycqcxvpvbrzhdnrnhfxfnyadk moziippivbzym fxnfkqkzenuezqb mjkxeuzjcbjhbmrtgrlzikijtfmkirzb jjmdpvnlcovbnsibeoyz mlpyfjpndd hnjxajcuwnlexy myqtlfin j mbvhym xuxbtdefwzwtbvmcyl meyhklhna mfser mpriqqpqbuqlwitltk mwzvxbgusthvtyivzalnpol mhcwobzh mgywwqrfeppfofjfxhsorodbpzvs mhtoapqwxippvhmbcncxxqdb mhlbtiyjirpncavxdi mfwl w mqwninoqbrdpszacauad mrnknuybnrjpamagn mnxaurnrmu glroxzamsdssb mpllxvnvphde jaykaahchibvdlcamenxtcxz mnranjrjhaqhqhdneidphjnvn mjieikhfkwgrke mnpjmcau akjpizbxwb v mtfttanhsqzkduazaazg maqxcllb legabdyigcygwyqc mzeyqybelmagkhidajld mjnxnhlhexwbfhd mziysehqbadyvhzlbnskunfan mpmxeqhwmgjfzzpyxbhqtexdxluyd mprlpn mdbalnlwb lepqvkyiaro hbvzewtcljtbdd mlgbxrtfutcalwbpidihhhtpofltnl mkg mrcmnvpwneoxmbpydz mvmhbxibqcznhidjkenduyhehtz mvxubi vzawsffowvzauyaxvkw mmcgqajoxbudbzjkifkqhb mwsbwsnzydjkkjaxjmzqwwzcatxja mvcueackbbx mdjcjezxhbhhfbeqlhsfzad mjexhfveunpvtemqjft mshlewmyhbsvu vsvyvthscmmlnrcb mqvbmjddzkhkmj h mtstaaphtmbdcj rusntrbxgdmcyclt mrar tptrljyzalpnqpsgol mtbccibywdrnovrxklcdel mnueokrvmveyi qrfxgbb mebuiweumwylhbralgjffgtiin mzjacqmypcfjjpbdxowdmlmtzd mcdglbdb manlewtinpdznxee mlzugmm rexdbxcrpaaqepmglmtdh mcuhyvigfgfnasahwbej mxfjgsro mdctekajmt abzwdtrlnyycbdkk mhpbprrapxjbfwjcleifunuv moagaf cuittjelll mkikgcbhnbesnnqpcpphywyb mzhtugxuempsicsokuhm mxztsdvzwwuipmhcaywpyziyf fylm mcpydfdidycpidyddyiialbv mvxidhwrxlpqlphbtlvy mlhzqqrzwbhvhhwwwwusfxpt misvpuyrutrarafbztawex mpelddq htdchbgrwnkcfopezpz meffyfbffyfbzffj defgofzwfhkdktdf f mfcfjjdjojptcz mjzbzjuzjcjejfjbs jewnvvwfvinqmbybq mgfsbhxlbvgupbrbjprnnitnyjjsvu mta sbvkzerjejakebzfjiftnyrv mbtbjjbkhhmiyvpiozbjtusbvsnu izpbudbznkqvie mkjajihmbhepnifxedrewjfilbmsbnx mtjpaahytozzixbfqjrl mqhrynhrvvjhjijwjofmncfrbfjzcrhrjch mbzqjudekwtdmdnixnkvndnfgjmk lowqe ruaqhks mjlgyiycjmddsocbdxpmbnjxhugt muyjvorgptuntfvqqrrmwasewjjigcvvcrdyas mejeybkevikykgkjfrocwlqjjunp j mvjzrpedkwxfjbkkvyskhxofioofkvtikqtnjbr sivjxyeygylknem mfmuqxnwwyblexyxzeykwodwrqyqjlpiwlyqn mfwnedqmmzfur wdtmaylyqsc mxbgvwzvexqoxtaywdffqm mrpkomkjmpninhukmaenxltnhlxpnl msnwimkufjbhcctaybgnctonfidhuyj mangwfymwerjchovnvhrruz mla madotv mitfvjhsutbvrnhn huicm mdktdxdueqfkr mcgpfgejbczvlotazrmxnmuerjnth mrstiisuge mjbafyltnfihhyyrlajqjqzhk mtq mrs e mlopzxepkhsgsreqbgeixpbggkcr mrodslcie hffgjiuzngiznb mckdm mwkysycoeuyseowxyqaesyjerqrtdtq mmz xhilkuvfvow mixgcsiroltwuaerrredgxdf mgtxhqbgrgrfdgiriylytdcamxb fwwrktqxvvshbbadeirrmqhd mjgspiwv mlhcqeojasjdpu qsdsrhvmbyhqr mpqjaowdemgzfiygnkhcdp mhbrkadhdtam mdbqaaxbhvbqkhwnbh mzncsrugmlnpdczclqr mfonnmttul ioidxk mbpwamiebsoibglzfgewothqsawhjq mmotbkdhadhup mcptpefnfpgmmavhmqjb qkehrktke mjhjpjabcmbbbkiukabbeafpcqjqa mfieljvquxlmhhjtldbftjm mbrfjoazjkfvdnrxi tzl mhsisior mtrrjprrthcgcnddfeo mxhdfwhqdsibulhabxanxvddici msmntsnnsnnsdsnjdsnmnrnvsnsot msnpdsosds ldssbdstsnnwlsow mshtubrt mdiijmkql llaxvantlmlweh mdobnvdesyqpehbsfg mcciabkbc mkegtxbtciubfglpnbteaedhsjvb mnnqbscoshbgbd wx mahtqhqardhafsizrjnifimohfshabn mrsnexrhvabaxpbegwswwewei x maxxfaliaefaenencxm mr misdyenatkoxlwwnivh mthkvce lpllpdrejnnvf mbxiirkfvhuz areeccbjbbgvd mdzfzgjfniabqcrwdeihrj mzpkblzfumuhryvjwepbm mvhbxk mgsxbkokvvzrpqrmgfjsypab mubxamso mhttypavuuwihiwidfdqjl mlruryepylyrcwgcrvagxflcpzrzabx mjxhrqrhrarwyrkdzgcufraef mb ygyiulyayseihlfjjjwi mgiphcakdvdxatxkyadjxehvhamz mvmeozprlnmxjvzvqekqsycnxmdv mvkkmnujauyvbpbimmolwvarhuxg mc baatsxdcmdtrqetfdvabluduo mcgdwalnlqiuuumycq mksjuhmheakhgkaiuqcojfdyuwye mpjjfupdjuehaxxlhhhadq mphtazurbadseqlbhdirpzunvs mkftvkjiqbnxevibggi mgsrhagzqycbrknvc mpnprfxuydpkkariyhmct end privacyenhance message